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General introduction 
Vitamin K antagonists (VKAs) are among the most commonly prescribed 
drugs in western countries. They are used by approximately 2% of the 
population1;2 and this number has kept growing over the past decade. VKAs 
are used to treat and prevent thrombosis. Their effectiveness for various 
indications has been proven in many well-designed studies. Indications 
include atrial fibrillation,3 deep vein thrombosis, pulmonary embolism4 and 
heart valve prostheses.5 
Unfortunately, therapy with VKAs is not without drawbacks. One 
important limitation is their narrow therapeutic window: When, on the one 
hand, the intensity of anticoagulation, expressed as the International 
Normalized Ratio (INR) is too low, the risk of thrombosis increases up to 
that of untreated patients.6-8 When, on the other hand, the INR is too high, 
the risk of bleeding complications increases sharply.6;7;9 A second limitation 
of VKAs is the considerable variability in anticoagulant response. Not only 
does the required dose vary significantly between patients, but also VKAs 
are subject to interactions with drugs and diet, so the anticoagulant 
response for a particular patient often fluctuates over time. Because of these 
two properties (the narrow therapeutic window and the variability in 
anticoagulant response) the INR needs to be monitored closely and dose 
adjustments often need to be made. Despite intensive monitoring by 
specialized anticoagulation clinics, the INR is within the target range only 
65-75% of time.6 Side effects can be serious and account for 8% of 
medication-related hospital admissions.10 While the narrow therapeutic 
window is inherent to treatment with VKAs, the variability in anticoagulant 
response can be influenced and knowledge about interactions is essential to 
improve quality of treatment. This thesis describes a series of studies 
investigating the effect of the most obvious interacting agent with vitamin 
K antagonists: vitamin K. 
 
Mode of action vitamin K antagonists 
As their name suggests, vitamin K antagonists act by inhibiting vitamin K 
metabolism.6 Vitamin K is essential for the synthesis of various proteins 
involved in blood coagulation, among which the clotting factors II, VII, IX 
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and X. These proteins undergo a post-translational modification that is 
required for them to function: Glutamate residues (Glu) are carboxylated to 
γ-carboxyglutamate (Gla). The carboxylation reaction occurs in the liver and 
is performed by γ-glutamyl carboxylase. This enzyme requires vitamin K in 
its reduced form (vitamin K hydroquinone) as a cofactor. During the 
carboxylation reaction, the vitamin K hydroquinone is converted to its 
inactive metabolite, vitamin K epoxide, which is subsequently converted 
back to vitamin K hydroquinone by vitamin K epoxide reductase (VKOR). 
Vitamin K antagonists inhibit VKOR, thereby blocking the turnover of 
vitamin K epoxide resulting in depletion of the active vitamin K stores. This 
leads to the desired anticoagulant effect due to reduced production of fully 
carboxylated vitamin-K dependent clotting factors. 
 
Treatment with vitamin K antagonist 
World-wide, warfarin is the most commonly prescribed VKA. In the 
Netherlands, acenocoumarol and phenprocoumon are used. The intensity 
of anticoagulation is determined by measuring the prothrombin time and 
expressed as the International Normalized Ratio (INR).6 The INR was 
introduced in the early 1980s to standardize the highly variable prothrombin 
time assays. Many studies have been performed to determine the optimal 
intensity of the INR. In the Netherlands two target ranges are used, 
according to the guidelines of the Federation of Dutch Anticoagulation 
Clinics: INR 2.5 - 3.5 for low intensity treatment and INR 3.0 - 4.0 for high 
intensity treatment.11 These ranges differ from the internationally used 
ranges, which are lower. The reason for these higher target ranges is to 
minimize the risk of subtherapeutic INRs, which are more common in 
clinical practice than in clinical trials.12-14 
Genetic as well as many environmental factors influence the sensitivity 
to VKAs. Genetic factors include polymorphisms of the genes encoding a 
key enzyme in VKA metabolism (CYP2C9) and the VKA target enzyme 
VKOR (VKORC1). Environmental factors include drugs, diet and various 
disease states.6;15 As a consequence, patients using VKAs need to be 
monitored at intervals of 1-6 weeks and the dosage is adjusted according to 
the INR result.6 In the Netherlands, treatment with VKAs is most often 
managed by specialized anticoagulation clinics.16 
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Many developments have led to an improved quality of oral 
anticoagulant therapy with VKAs in the past: the introduction of the INR, 
the emergence of anticoagulation clinics,17 computer aided dosing,18;19 the 
establishment of the optimal target range20;21 and progress in knowledge of 
interacting drugs.22;23 Even today treatment with VKAs is in development: 
Patient self-testing of the INR using capillary blood obtained with a finger-
prick has become increasingly common and allows patients to manage their 
anticoagulant treatment themselves.24;25 Genotyping of patients to guide 
dosing is being investigated.26;27 The different VKAs have been compared 
and have been shown to differ in quality of control, probably related to 
differences in their half-lives.28;29 And even though the influence of dietary 
vitamin K intake has always been generally accepted, it was not until the last 
decade that more attention has been paid to this topic. 
 
Vitamin K and vitamin K antagonists 
The effect of pharmacological doses of vitamin K to lower the INR in case 
of overanticoagulation, bleeding complications or invasive procedures is 
well known.30 The influence of physiological vitamin K intake on stability of 
oral anticoagulant treatment has had less attention in medical research. 
Knowledge of the effect of vitamin K intake on anticoagulant therapy has 
been based mainly on case reports and a few small experimental studies 
with extremely high vitamin K intakes.31 In 2004, two studies on the 
influence of dietary vitamin K on the anticoagulant response were 
published.32;33 These confirmed that the INR is influenced by dietary 
vitamin K intake and suggested that this influence is higher at a lower 
average vitamin K intake. This was supported by a study that showed that 
in patients with a low vitamin K status, even daily supplement doses as low 
as 25 microgram gave an important decrease of the INR, which was not 
observed in patients with a normal vitamin K status.34 Sconce et al. reported 
that patients with a poor vitamin K intake had a more unstable control of 
anticoagulation.35 Together, these studies support the hypothesis that the 
INR is relatively resistant to changes in vitamin K intake when average 
vitamin K intake is high. We set out to test this hypothesis and investigate 
whether supplementation with a low daily dose of vitamin K may improve 
anticoagulant stability. 
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Outline of this thesis 
In chapter 2 we describe a cohort study that we performed to determine the 
risk of subtherapeutic INRs in routinely treated patients. Within the cohort 
a nested case-control study was performed to identify risk factors associated 
with a low INR and to determine how often a subtherapeutic INR is the 
result of medical interference in case of invasive procedures, hospital 
admissions, haemorrhage or overanticoagulation.  
In chapter 3 we investigated the association between dietary vitamin K 
intake and the risk of subtherapeutic INRs. In a nested case-control study 
we determined the effect of both usual vitamin K intake, consumed over a 
longer period of time, and recent vitamin K intake. Also the interaction 
between usual and recent vitamin K intake was studied to determine 
whether the effect of an incidental increase in vitamin K intake differs 
between patients with a low or high usual vitamin K intake.  
In chapter 4 we present a pilot study that was performed to determine 
the highest dose of vitamin K that can safely be given to patients using 
VKAs. We studied the effect of escalating daily doses of vitamin K on the 
required dose of phenprocoumon. This vitamin K dose was used in the trial 
described in chapter 5.  
In chapter 5 we present a double blind, randomized, placebo-controlled 
trial that studied whether supplementation with a low daily dose of vitamin 
K improves anticoagulant control. Patients were randomized to receive 
either phenprocoumon and 100 µg vitamin K once daily or 
phenprocoumon and a placebo. The primary outcome is the percentage of 
time the INR is within the therapeutic range.  
Chapter 6 describes a study performed to determine whether there is an 
association between vitamin K status and stability of anticoagulant 
treatment. In participants of the trial presented in chapter 5, we examined 
the relationship between serum vitamin K1 and its metabolite, 
vitamin K 2,3-epoxide and stability of anticoagulant treatment. 
In chapter 7 we evaluate the use of a new computer algorithm that was 
developed to improve computer aided dosing of VKAs. The new computer 
algorithm (ICAD) was compared, in a double blind randomized controlled 
trial, to an algorithm that is frequently used in the Netherlands (TRODIS). 
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The aim of this research is to provide insight in causes of unstable 
anticoagulant control, and subtherapeutic anticoagulation in particular. 
Because the risk of adverse events is inversely associated with stability of 
anticoagulation, knowledge of what influences stability will help to prevent 
thrombotic and bleeding complications. In the summary section we will 
translate our findings into clinical implications and recommendations for 
future research.  
  13 
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Abstract 
Background 
Subtherapeutic anticoagulation levels increase both the risk and severity of 
thromboembolism. The aim of this study was to determine the cumulative 
incidence of subtherapeutic international normalized ratios (INRs) and to 
identify risk factors associated with a low INR. 
Methods 
We performed a cohort study in 7 419 patients from a Dutch 
anticoagulation clinic. Patients who started a first treatment with oral 
anticoagulants between January 2000 and December 2005 and who were 
stably anticoagulated (4 consecutive INRs in the therapeutic range) were 
included. Within the cohort a nested case-control study was performed to 
identify risk factors of subtherapeutic INRs and to determine how often a 
subtherapeutic INR is the result of medical interference in case of invasive 
procedures, hospital admissions, hemorrhage or overanticoagulation. 
Results and conclusions 
In patients with a stable anticoagulation, the median time to a first low INR 
was 40 weeks. A subtherapeutic INR occurred twice as often in patients 
using acenocoumarol as in those using phenprocoumon (hazard ratio [HR] 
2.1, 95% Confidence Interval [95%CI]: 2.0-2.3) and was more common in 
patients with a high therapeutic range compared to a low therapeutic range 
(HR 1.8, 95%CI: 1.5-2.2). Occurrence of a low INR also depended on 
indication for anticoagulant therapy, with the highest risk in patients who 
used anticoagulants as prophylaxis and the lowest risk in patients with 
mechanical heart valves. In 30% of cases the subtherapeutic INR was 
preceded by an event necessitating vitamin K or discontinuation of the 
anticoagulant drug. 
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Introduction 
Oral anticoagulant therapy with vitamin K antagonists has been proven 
effective in primary and secondary prevention of both venous and arterial 
thrombosis.1-3 Treatment with these drugs requires careful monitoring 
because of a narrow therapeutic range. When the intensity of 
anticoagulation (expressed as the International Normalized Ratio or INR) is 
high the risk of bleeding events is increased.4-6 Low INRs increase not only 
the frequency of thromboembolism but also its severity and the associated 
risk of death.6-11 
Despite frequent monitoring of the INR, subtherapeutic 
anticoagulation is common. In primary prevention trials, the INR was 
below the target range 8 to 40% of the time.12-16 In clinical practice, time 
below the target range of up to 26-52% has been reported.8;9;17 These 
numbers depend strongly on the target range used. In addition, in the initial 
phase of oral anticoagulant therapy patients spend more time below the 
target range than during long-term use, since it usually takes some time 
before stable anticoagulation is achieved. Time in, above or below the 
therapeutic range can thus vary widely between populations. 
Much research has been done on causes of overanticoagulation and 
unstable anticoagulant control.18-21 Causes of subtherapeutic anticoagulation 
are less well understood. In order to improve anticoagulant control, it is 
also important to identify risk factors for subtherapeutic INRs and to 
recognize how often these are the result of discontinuation of the 
anticoagulant drug in case of surgery, invasive procedures or bleeding. 
The aim of this study was: 1. To determine the frequency of low INR 
values in patients who are stably anticoagulated, 2. To identify risk factors 
for subtherapeutic INRs and 3. To determine the contribution of vitamin K 
administration or discontinuation of the anticoagulant drug to the risk of 
developing a subtherapeutic INR. 
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Methods 
Study design 
We performed a retrospective follow-up study within a cohort of patients 
from the Leiden anticoagulation clinic. The cohort consisted of all patients 
who started a first treatment with oral anticoagulants between January 2000 
and December 2005 and who had reached stable anticoagulation. Stable 
anticoagulation was defined as four consecutive INRs in the therapeutic 
range. The therapeutic range was defined as agreed by the Federation of 
Dutch Anticoagulation Clinics: INR 2.0-3.5 (target INR 3.0) for low 
intensity and 2.5-4.0 (target INR 3.5) for high intensity treatment. Patients 
in the cohort were followed from the date they reached stability until the 
first subtherapeutic INR, the end of treatment, an interruption of follow-up 
for more than 9 weeks or at the end of the study period. Because follow-up 
ended when a patient had a subtherapeutic INR, patients in the cohort had 
therapeutic or high INRs only. 
Within this cohort we performed a nested case-control study. Cases 
were all patients who, after reaching stable anticoagulation, had a first 
subtherapeutic INR. For each case a control patient was selected from the 
cohort, who had an INR measurement on the same day as the case (index 
date) and had not yet had a subtherapeutic INR. This method is known as 
incidence density sampling. The Odds Ratio (OR) calculated from case-
control studies using incidence density sampling is a valid estimation of the 
Rate Ratio, even if the outcome under study is frequent.22 Controls were 
matched individually to the cases on duration of treatment. For both cases 
and controls computer records were checked for any of the following 
events in the four weeks prior to the index date: invasive procedures, 
hospital admissions, hemorrhages, an INR >7.0, use of vitamin K or 
discontinuation of the anticoagulant drug for two or more days. The four-
week window was chosen to account for the long half-life of 
phenprocoumon. 
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Setting 
In the Netherlands, all patients on oral anticoagulants are treated by 
specialized anticoagulation clinics. This study was performed at the Leiden 
anticoagulation clinic, where nearly 10 000 patients are treated each year. 
Patients are seen by trained nurses every 1-6 weeks. At every visit, blood for 
an INR measurement is collected via venipuncture and the patient is asked 
to report any special circumstances, such as non-compliance, bleeding 
episodes, changes in co-medication, hospital visits or (surgical) procedures. 
The history is taken according to the anticoagulation clinic’s quality 
guidelines. Because the history is taken before the INR result is known, the 
information was obtained in a similar manner for cases and controls. INR 
results and prescribed dosages are recorded in a central database, along with 
relevant history details and information on admissions and interventions.  
The following bleeding episodes are recorded: All intracranial, 
retroperitoneal, muscle, joint, ocular and subconjunctival bleeds, all 
hemorrhage from the gastro-intestinal, respiratory and urogenital tracts, 
epistaxis when longer than 30 minutes and bruises more than 10 cm in 
diameter. 
Two oral anticoagulant agents are available in the Netherlands, 
acenocoumarol (with a half-life of 8-11 hours [h]) and phenprocoumon 
(Marcoumar®, half-life approximately 160 h). In the Leiden anticoagulation 
clinic phenprocoumon is used by approximately 90% of patients.  
Indications for anticoagulant therapy are categorized as follows: Atrial 
fibrillation, secondary prevention venous thrombosis (any venous 
thrombotic event), mechanical heart valves (mitral and/or aorta), arterial 
indications (primary and secondary prevention of myocardial infarction, 
stroke and peripheral embolism) and prophylaxis (primary prevention of 
venous thrombosis after surgery or in other high-risk situations) 
 
Analysis 
In the full cohort, we used the Kaplan-Meier method to estimate the risk of 
subtherapeutic INRs in patients with a stable anticoagulation. Time to a 
first subtherapeutic INR was defined as the time between obtaining a stable 
anticoagulation and the date of a first subtherapeutic INR. Patients were 
censored at the end of treatment, at the end of the study period or when 
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follow-up was interrupted for more than nine weeks. The effect of patient 
and treatment characteristics on the risk of a low INR was evaluated with 
Cox proportional hazards regression.  
ORs for the transient risk factors in the case control analysis were 
calculated with conditional logistic regression. 
 
Results 
During the study period 13 443 patients started a first treatment with oral 
anticoagulants. Of those, 7 419 reached stable anticoagulation, i.e. had four 
consecutive INRs within the target range. The average time to stable 
anticoagulation was 12 weeks (range 1 -211 weeks). Of those patients that 
did not reach stable anticoagulation, the average follow-up time was seven 
weeks (range 0 -133 weeks). The total follow-up time of stable patients was 
4 037 patient-years, the average follow-up time per patient was 28 weeks 
(range 0 -304 weeks. Of the 7 419 stable patients, 3 166 had one or more 
subtherapeutic INRs during follow-up. 
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Figure 1: Kaplan-Meier curve of the likelihood of a subtherapeutic INR in patients with a 
stable anticoagulation. On the x-axis time since stable anticoagulation. On the y-axis the 
proportion of patients who had a subtherapeutic INR. 
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There were two thromboembolic events in the period between the last 
known INR before - and the first non-subtherapeutic INR after the 
subtherapeutic episode. One patient had an ischemic stroke 6 days before 
the index-date for which she was admitted (INR at admission unknown). 
One patient suffered a mechanical valve thrombosis and survived 
cardiopulmonary resuscitation 8 days after the index-date (INR at admission 
2.3).  
Figure 1 shows the Kaplan Meier curve of the risk of a first 
subtherapeutic INR in stable patients. After four weeks 12% of patients had 
had a subtherapeutic INR. This increased to 21% at 8 weeks and after 40 
weeks 50% had had a low INR.  
 
 
 
Table 1: Patient characteristics and the median time to a first subtherapeutic INR in 
different patient groups. *Adjusted for sex, age, anticoagulant used, target range, and indication 
category. HR, Hazard Ratio; 95%CI, 95% confidence interval 
 Number of 
patients 
(percentage) 
Median time 
to a low INR 
(weeks - 
95%CI) 
Crude HR  
(95%CI) 
Adjusted HR* 
(95%CI) 
Sex     
Male (ref) 3788 (51%) 42 (38-46) 1 1 
Female 3631 (49%) 37 (33-40) 1.12 (1.04-1.20) 1.07 (0.99-1.15) 
Anticoagulant     
Phenprocoumon (ref) 5748 (78%) 51 (47-55) 1 1 
Acenocoumarol 1639 (22%) 13 (12-15) 2.30 (2.12-2.50) 2.14 (1.96-2.33) 
Therapeutic range     
Low (2.0-3.5) (ref) 6351 (86%) 48 (44-52) 1 1 
High (2.5-4.0) 1068 (14%) 21 (19-23) 1.58 (1.46-1.71) 1.83 (1.53-2.19) 
Age     
< 50 years 1337 (18%) 26 (21-31) 1.30 (1.18-1.44) 1.15 (1.03-1.29) 
50 - 70 years 2812 (38%) 42 (37-47) 0.96 (0.89-1.03) 0.93 (0.86-1.00) 
>70 years (ref) 3270 (44%) 42 (38-46) 1 1 
Indication     
Atrial fibrillation (ref) 2778 (37%) 58 (52-64) 1 1 
Secondary prevention 
venous thrombosis 
1544 (21%) 31 (25-37) 1.45 (1.31-1.61) 1.36 (1.21-1.52) 
Mechanical heart 
valves 
189 (3%) 66 (41-91) 0.95 (0.78-1.16) 0.69 (0.56-0.86) 
Arterial indications 1229 (17%) 23 (20-26) 1.67 (1.53-1.82) 0.96 (0.81-1.15) 
Prophylaxis 1679 (23%) 14 (10-19) 2.51 (2.20-2.86) 1.88 (1.64-2.16) 
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There was no difference in risk of a subtherapeutic INR between men 
and women (Table 1). Patients aged younger than 50 years had a slightly 
increased risk of a low INR. Use of the anticoagulant drug acenocoumarol 
doubled the risk compared to the longer acting phenprocoumon (adjusted 
HR 2.14, 95%CI: 1.96-2.33). In patients using acenocoumarol the median 
time to a first subtherapeutic INR was 13 weeks compared to 51 weeks in 
the phenprocoumon group. In patients with an indication for high-intensity 
treatment the median time to a first low INR was 21 weeks, compared to 48 
weeks in patients with low intensity treatment. (adjusted HR 1.83, 95%CI: 
1.53-2.19). Occurrence of a subtherapeutic INR also depended on 
indication for treatment, with the highest risk in patients who used oral 
anticoagulants as prophylaxis for venous thromboembolism and the lowest 
risk in patients with mechanical heart valves (Table 1). 
A low INR was preceded by an event necessitating discontinuation of 
treatment in 30% of cases (Table 2). These were mainly invasive procedures 
(11.2% of cases, 1.0% of controls), surgical admissions (6.5% of cases, 1.6% 
of controls) and hemorrhages (5.9% of cases and 1.7% of controls). 
Vitamin K was used in the four weeks preceding the index date by 14.2% of 
cases and 2.9% of controls. Of the patients undergoing an invasive 
procedure 70% of cases received vitamin K versus 81% in control patients. 
Treatment was discontinued for two or more days in 5.4% of cases and 
0.8% of controls. 
 
Discussion 
After reaching stable anticoagulation fifty percent of patients had a 
subtherapeutic INR within 40 weeks. We chose to present the cumulative 
incidence in patients with a stable anticoagulation, because patients with a 
low INR are not at risk for getting a low INR. The criteria for a stable 
anticoagulation (4 consecutive INRs in the therapeutic range) were 
stringent, and were met by only approximately half of patients. This must 
be kept in mind when interpreting the results: In patients starting treatment 
with vitamin K antagonists the risk of underanticoagulation will be higher. 
In these patients many of the subtherapeutic INRs will be caused by too 
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low dosages of the anticoagulant drug, because it usually takes some time 
before the right dosage is known for an individual patient.  
Two patients suffered a thromboembolic event in the period before 
and after the subtherapeutic INR. The design of our study was not suited to 
calculate an absolute risk. Furthermore, it is difficult to estimate the risk 
period, because the duration of the subtherapeutic INR before the index-
date and after the last low INR is unknown.  
We found several patient and treatment characteristics that were 
associated with the risk of underanticoagulation. A possible explanation for 
the difference in frequency of occurrence of subtherapeutic anticoagulation 
amongst the indication categories may be a difference in compliance: The 
risk was highest in patients who used anticoagulation as primary prophylaxis 
for venous thromboembolism and lowest in patients with mechanical heart 
valves, who have the highest underlying risk of thrombosis. The increased 
risk for patients with an arterial indication disappeared completely after 
adjustment for target range, indicating that the latter is the real association. 
One possible explanation for the higher risk of a subtherapeutic INR in 
high therapeutic range patients is that dosing physicians are more inclined 
to lower the dose when the INR is high in range in these patients than in 
the low therapeutic range patients. The most striking difference was 
between phenprocoumon and acenocoumarol. Fifty percent of patients 
using acenocoumarol had a subtherapeutic INR after 13 weeks compared to 
51 weeks in patients using phenprocoumon. This finding is consistent with 
reports that longer-acting vitamin K antagonist give a more stable 
anticoagulation than short-acting vitamin K antagonists.23-25  
Thirty percent of cases of a subtherapeutic INR were preceded by a 
bleeding episode, a surgical or medical admission, an invasive procedure or 
by an INR >7.0. Invasive procedures gave the highest risk of a low INR. 
Because the anticoagulant drug was withheld or vitamin K was given in 
nearly all patients, this is not surprising. Vitamin K is given to a relatively 
large proportion of patients, because in our study population 78% of 
patients use the long-acting phenprocoumon. However, vitamin K was 
given in even more control patients than case patients who underwent an 
invasive procedure. This suggests that in this study population 
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administering vitamin K peri-intervention reduced the risk of a 
subtherapeutic INR compared to withholding the anticoagulant drug. 
The risk was lower in patients who were admitted for a surgical 
intervention than in outpatients undergoing an invasive procedure, although 
one would have expected similar risks. It is possible that subtherapeutic 
INRs occurred during admission but were adjusted before the end of the 
admission. Admissions for non-surgical reasons also led to a subtherapeutic 
INR, but less often. Even though overanticoagulation was common (INR > 
7.0 in 1.6% of the controls) and vitamin K was given in nearly all patients, 
the relative risk of a low INR after an INR above 7.0 was only 1.6. This 
suggests that over-correcting, though present, is not a major cause of a 
subtherapeutic INR. 
Subtherapeutic anticoagulation in patients using vitamin K antagonists 
is common and can have severe consequences. Our results give insight in 
the risk of subtherapeutic anticoagulation for an individual patient in the 
outpatient setting. We have shown that  subtherapeutic INRs are common 
and that thirty percent of all subtherapeutic INRs could be explained by 
events necessitating discontinuation of the treatment, leaving 70% that were 
unintended. We have described risk factors that contribute to these low 
INRs and that can be used to prevent them. A first step can be the 
preferential use of long acting anticoagulants, such as phenprocoumon. 
Whether the differences in risk between indications are the effect of 
avoidable causes such as patient compliance or dosing strategies remains to 
be determined. 
 28 
References 
 1.  Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of 
antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five 
randomized controlled trials. Arch.Intern.Med. 1994;154:1449-1457. 
 2.  Lagerstedt CI, Olsson CG, Fagher BO, Oqvist BW, Albrechtsson U. Need for long-
term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 
1985;2:515-518. 
 3.  van Walraven C, Hart RG, Singer DE et al. Oral anticoagulants vs aspirin in 
nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 
2002;288:2441-2448. 
 4.  Ansell J, Hirsh J, Hylek E et al. Pharmacology and management of the vitamin K 
antagonists: American College of Chest Physicians Evidence-Based Clinical Practice 
Guidelines (8th Edition). Chest 2008;133:160S-198S. 
 5.  Reynolds MW, Fahrbach K, Hauch O et al. Warfarin anticoagulation and outcomes 
in patients with atrial fibrillation: a systematic review and metaanalysis. Chest 
2004;126:1938-1945. 
 6.  Cannegieter SC, Rosendaal FR, Wintzen AR et al. Optimal oral anticoagulant 
therapy in patients with mechanical heart valves. N.Engl.J.Med. 1995;333:11-17. 
 7.  Hylek EM, Go AS, Chang Y et al. Effect of intensity of oral anticoagulation on 
stroke severity and mortality in atrial fibrillation. N.Engl.J.Med. 2003;349:1019-1026. 
 8.  Go AS, Hylek EM, Chang Y et al. Anticoagulation therapy for stroke prevention in 
atrial fibrillation: how well do randomized trials translate into clinical practice? 
JAMA 2003;290:2685-2692. 
 9.  Kalra L, Yu G, Perez I, Lakhani A, Donaldson N. Prospective cohort study to 
determine if trial efficacy of anticoagulation for stroke prevention in atrial 
fibrillation translates into clinical effectiveness. BMJ 2000;320:1236-1239. 
 10.  Wyse DG, Waldo AL, DiMarco JP et al. A comparison of rate control and rhythm 
control in patients with atrial fibrillation. N.Engl.J.Med. 2002;347:1825-1833. 
 11.  Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective 
intensity of prophylactic anticoagulation for patients with nonrheumatic atrial 
fibrillation. N.Engl.J.Med. 1996;335:540-546. 
 12.  The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic 
atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation 
Investigators. N.Engl.J.Med. 1990;323:1505-1511. 
 13.  Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991;84:527-
539. 
 14.  Connolly SJ, Laupacis A, Gent M et al. Canadian Atrial Fibrillation Anticoagulation 
(CAFA) Study. J.Am.Coll.Cardiol. 1991;18:349-355. 
 15.  Ezekowitz MD, Bridgers SL, James KE et al. Warfarin in the prevention of stroke 
associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention 
in Nonrheumatic Atrial Fibrillation Investigators. N.Engl.J.Med. 1992;327:1406-
1412. 
 16.  Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-
controlled, randomised trial of warfarin and aspirin for prevention of 
thromboembolic complications in chronic atrial fibrillation. The Copenhagen 
AFASAK study. Lancet 1989;1:175-179. 
 29 
 17.  Samsa GP, Matchar DB, Goldstein LB et al. Quality of anticoagulation management 
among patients with atrial fibrillation: results of a review of medical records from 2 
communities. Arch.Intern.Med. 2000;160:967-973. 
 18.  Penning-van Beest FJ, van Meegen E, Rosendaal FR, Stricker BH. Characteristics of 
anticoagulant therapy and comorbidity related to overanticoagulation. 
Thromb.Haemost. 2001;86:569-574. 
 19.  Penning-van Beest FJ, van Meegen E, Rosendaal FR, Stricker BH. Drug interactions 
as a cause of overanticoagulation on phenprocoumon or acenocoumarol 
predominantly concern antibacterial drugs. Clin.Pharmacol.Ther. 2001;69:451-457. 
 20.  Palareti G, Legnani C, Guazzaloca G et al. Risks factors for highly unstable 
response to oral anticoagulation: a case-control study. Br.J.Haematol. 2005;129:72-
78. 
 21.  Cadiou G, Varin R, Levesque H et al. Risk factors of vitamin K antagonist 
overcoagulation. A case-control study in unselected patients referred to an 
emergency department. Thromb.Haemost. 2008;100:685-692. 
 22.  Szklo M, Nieto FJ. Basic Study Designs in Analytical Epidemiology. Epidemiology: 
beyond the basics.: Jones and Bartlett Publishers; 2004:3-51. 
 23.  Gadisseur AP, van der Meer FJ, Adriaansen HJ, Fihn SD, Rosendaal FR. 
Therapeutic quality control of oral anticoagulant therapy comparing the short-acting 
acenocoumarol and the long-acting phenprocoumon. Br.J.Haematol. 2002;117:940-
946. 
 24.  Fihn SD, Gadisseur AA, Pasterkamp E et al. Comparison of control and stability of 
oral anticoagulant therapy using acenocoumarol versus phenprocoumon. 
Thromb.Haemost. 2003;90:260-266. 
 25.  Pattacini C, Manotti C, Pini M, Quintavalla R, Dettori AG. A comparative study on 
the quality of oral anticoagulant therapy (warfarin versus acenocoumarol). 
Thromb.Haemost. 1994;71:188-191. 
 

 3 
Influence of dietary vitamin K intake 
on subtherapeutic oral anticoagulant 
therapy 
 
 
 
 
 
 
 
 
 
 
 
 
E.K. Rombouts, F.R. Rosendaal, F.J.M. van der Meer 
 
British Journal of Haematology. 2010; 149: 598-605 
 32 
Abstract 
Background 
It is unclear what advice should be given to patients using vitamin K 
antagonists with respect to dietary vitamin K intake. 
Methods 
We performed a nested case-control study in patients attending a Dutch 
anticoagulation clinic, to determine the association between vitamin K 
intake and subtherapeutic International Normalized Ratio (INR) values and 
the interaction between usual and recent vitamin K intake. 
Results 
Compared to patients with a normal usual vitamin K intake, those with a 
high vitamin K intake had a decreased risk of a subtherapeutic INR [Hazard 
Ratio (HR) 0.80, 95%CI: 0.56-1.16) and patients with a low vitamin K 
intake an increased risk (HR 1.33, 95%CI: 0.79-2.25). In patients with a low 
usual vitamin K intake, recent vitamin K intake was twice as high in cases as 
in controls (164 vs 85 µg/d). Such a difference was not observed in patients 
with a normal or high usual vitamin K intake.  
Conclusions 
Our results suggest that a high vitamin K intake reduces the risk of a low 
INR by lessening the influence of incidental consumption of vitamin K rich 
food on the INR. These findings support the recommendation for patients 
on vitamin K antagonists to eat a sufficient amount of vitamin-K containing 
foods. 
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Introduction 
Oral anticoagulant treatment with vitamin K antagonists is effective in the 
primary and secondary prevention of both arterial and venous thrombosis. 
Side effects are common, and are frequently caused by unstable 
anticoagulation. Hemorrhagic complications are more frequent when the 
INR is too high.1-3 When the INR is too low the risk of thrombosis is 
increased.1;3;4 It is therefore important to keep the INR within the 
therapeutic range. 
Many factors are associated with instability of oral anticoagulant 
treatment, the most important being the presence of intercurrent illnesses,5 
drug interactions,3 genetic factors6 and the anticoagulant drug used, 
particularly its half-life.7;8 Another factor that may influence the stability of 
anticoagulation is dietary vitamin K intake.9-11  
Vitamin K is an essential cofactor for the post-translational 
carboxylation of various proteins involved in blood coagulation, among 
which the procoagulant factors II, VII, IX and X. During the carboxylation 
reaction, the vitamin K hydroquinone is oxidized to vitamin K epoxide. 
Vitamin K epoxide must be recycled to the reduced form before it can be 
reused, a process that is catalyzed by vitamin K epoxide reductase (VKOR). 
Vitamin K antagonists inhibit VKOR, blocking the turnover of vitamin K 
and depleting the liver of its active vitamin K stores. This leads to the 
desired anticoagulant effect due to reduced production of vitamin-K 
dependent clotting factors.6 
The effect of pharmacological doses of vitamin K, prescribed in 
patients receiving vitamin K antagonists to lower the INR in case of 
overanticoagulation, bleeding complications or invasive procedures, is well 
known.3;12;13 Also, several studies have been performed to assess the short-
term effect of dietary vitamin K intake on the INR in patients treated with 
vitamin K antagonists. Results were as expected: An increased vitamin K 
intake was associated with a decrease in the INR and a decreased vitamin K 
intake with a rise of the INR.9;14;15 The influence of the usual dietary vitamin 
K intake, consumed over a longer period of time, has been less well studied. 
Because the dosage of the anticoagulant drug is adjusted according to the 
measured INR and thus indirectly to vitamin K intake, the effect of usual 
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vitamin K intake is also less predictable. One study showed that in unstable 
patients, vitamin K intake was considerably lower than in stably 
anticoagulated patients.10 Another study did not show any association 
between dietary vitamin K intake and the risk of overanticoagulation.16 We 
found no studies that investigated the association between dietary vitamin 
K intake and the risk of a subtherapeutic INR.  
To determine what advice can best be given to patients using vitamin K 
antagonists regarding vitamin K intake, it is necessary to know the effect of 
dietary vitamin K intake on the risk of both over- and under-
anticoagulation. The aim of this study was to determine the effect of dietary 
vitamin K intake on the occurrence of subtherapeutic INRs. Because 
changes in vitamin K intake are proportionally larger in people with a low 
usual vitamin K intake, we hypothesized that especially in these patients an 
incidental increase in vitamin K intake would be a risk factor for 
subtheraupeutic INRs, which would therefore occur frequently.  
 
Methods 
This prospective cohort study was performed to investigate the effect of 
usual vitamin K intake on the risk of a subtherapeutic INR. Within the 
cohort a nested case-control group was studied to assess the effect of recent 
vitamin K intake on the risk of a low INR and the interaction between usual 
and recent vitamin K intake.  
The cohort consisted of patients from the Leiden anticoagulation clinic 
in the Netherlands, who had a first episode of stable anticoagulation 
between 1 January 2005 and 20 December 2005. It included both patients 
who started treatment before 2005 and who reached stable anticoagulation 
for the first time during the study period as well as patients who started 
treatment and reached stable anticoagulation during the study period. Stable 
anticoagulation was defined as four consecutive INRs in the therapeutic 
range [as agreed by the Federation of Dutch Anticoagulation Clinics: INR 
2.0-3.5 (target INR 3.0) for low intensity and 2.5-4.0 (target INR 3.5) for 
high intensity treatment]. The cohort was restricted to patients who had 
reached stable anticoagulation in order to reduce variability in the risk of 
subtherapeutic INRs caused by other factors that are known to cause 
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instability: Dose finding of the vitamin K antagonist, changes in the use of 
interacting medication such as antibiotics or amiodarone and the presence 
of conditions or symptoms known to influence the anticoagulant effect, 
such as heart failure, post-operative anorexia, fever, etc. 
The main outcome was a subtherapeutic INR (<2.0 for low intensity 
<2.5 for high intensity treatment).  
Once patients had reached stable anticoagulation they received a 
questionnaire by mail, including a food frequency questionnaire (FFQ) to 
determine the usual vitamin K intake (see below). Patients were then 
followed until the first subtherapeutic INR, the end of treatment or the end 
of the study period (20 December 2005), whichever occurred first. During 
follow-up patients regularly attended the anticoagulation clinic for INR 
measurements and received standard care. 
Within the cohort we performed a nested case-control study. When 
patients had a first sub-therapeutic INR after stable anticoagulation they 
became a case. For each case, two control patients were selected who had 
an INR measurement on the same day as the case. Controls were patients 
from the same cohort, i.e., who had reached stable anticoagulation, but who 
did not at that time had experienced a low INR. By this method, controls 
were matched to the cases on duration of follow-up. Cases were allowed to 
have been entered in the study previously as a control patient but patients 
were selected as a control only once.  
Both cases and controls were contacted by telephone on the day of the 
INR measurement. Subjects were asked questions on special circumstances 
that may have contributed to the subtherapeutic INR such as invasive 
procedures, comorbidity, compliance and recent vitamin K intake. To avoid 
interviewer bias the interviewer was blind with respect to the INR result. 
Cases who had stopped anticoagulant therapy or had been given vitamin K 
were excluded from the analysis. 
Baseline demographic data and clinical data such as age, sex, indication 
for anticoagulation, therapeutic range and the anticoagulant drug used were 
retrieved from the anticoagulation clinic’s computer files. Comorbidity was 
derived from the questionnaire (self-reported) and the comorbidity score 
was calculated in a similar fashion to the Charlson comorbidity score,17 
adding 1 point for the presence of myocardial infarction, congestive heart 
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failure, peripheral vascular disease, cerebrovascular disease, chronic 
pulmonary disease, mild liver disease and diabetes, 2 points for moderate or 
severe renal disease, any malignancy, leukemia or malignant lymphoma, 3 
points for moderate or severe liver disease and 6 points for metastatic solid 
malignancy.  
Usual vitamin K intake was assessed using an FFQ, including those 
items that contribute most to vitamin K intake in the Dutch population, 
either because of a high vitamin K content, because of frequent 
consumption or a combination of those. This list was composed using a 
table of the vitamin K content of food items16 and the Dutch national food 
consumption survey carried out by the Netherlands Organization for 
Applied Scientific Research in 1997-1998.18 Fifty-seven questions were 
asked on 42 food items, 31 of which were vegetables or fruits, the others 
dairy, oils and miscellaneous. Based on the result of this food frequency 
questionnaire patients were categorized as having a low (<100 µg vitamin K 
per d), a normal (100-300 µg/d) or a high vitamin K intake (>300µg 
vitamin K per d).  
Recent vitamin K intake was estimated using a 48-h recall conducted 
over the telephone. Included in the questionnaire were those food items 
that contain the highest vitamin K intake per portion. We used the same 
table with the vitamin K content of foods,16 the Dutch national food 
consumption survey18 and normal serving sizes19 to calculate the average 
intake per portion. The 48-h recall included 32 items. 
In the analysis of the full cohort, we used the Kaplan-Meier method to 
calculate the risk of subtherapeutic INRs in patients with a stable 
anticoagulation. Time to a first subtherapeutic INR was defined as the time 
between stable anticoagulation and the date of a first subtherapeutic INR. 
Patients were censored at the end of treatment, at the end of the study 
period, when follow-up was interrupted for more than 9 weeks or when 
they received vitamin K or stopped taking their vitamin K antagonist. The 
effect of usual vitamin K intake on the risk of a low INR was evaluated 
with Cox proportional hazards regression. In the case control analysis the 
amount of vitamin K consumed in the 48 hours before the index date was 
compared between cases and controls. Adjustment for possible 
confounders (age category, sex and season of recent vitamin K intake 
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measurement) and the matching factor (time since stable anticoagulation) 
was performed using linear regression analysis. Odds ratios were calculated 
with conditional logistic regression. Statistical analyses were performed 
using SPSS version 12 (SPSS Inc, Chicago, Ill, USA).  
 
Results 
Of the 9 889 patients who were registered at the Leiden anticoagulation 
clinic between 1 January 2005 and 20 December 2005, 7 855 had reached 
stable anticoagulation prior to 1 January 2005, 877 did not reach stable 
anticoagulation and 1 157 reached a first episode of stable anticoagulation 
and received the questionnaire (Figure 1). 
 
 
 
 
Figure 1: Flow of patients during follow-up. 
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 7 No valid dietary recall 
 28 Other reasons 
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Table 1: Patient and treatment characteristics according to vitamin K intake category. Data 
are presented as number (percentage) of patients. * n = 36 
   
Vitamin K intake 
 
No. (%)  
of patients  
(n = 1 157) 
Normal  
(n = 526) 
Low  
(n = 61) 
High  
(n = 253) 
Missing  
(n = 317) 
Sex 
 Male  650 (56) 311 (59) 30 (49) 149 (59) 160 (50) 
 Female 507 (44) 215 (41) 31 (51) 104 (41) 157 (50) 
Age  
 < 50 years 154 (13) 77 (15) 15 (25) 27 (11) 35 (11) 
 50 - 70 years 428 (37) 215 (41) 19 (31) 101 (40) 93 (29) 
 >70 years  575 (50) 234 (45) 27 (44) 125 (49) 189 (60) 
Indication 
 Atrial fibrillation  606 (52) 276 (53) 28 (46) 142 (56) 160 (51) 
 Secondary prevention 
venous thrombosis 
262 (23) 119 (23) 19 (31) 46 (18) 78 (25) 
 Mechanical heart valves 37 (3) 19 (4) 2 (3) 7 (3) 9 (3) 
 Arterial indications 151 (13) 74 (14) 9 (15) 36 (14) 32 (10) 
 Prophylaxis 101 (9) 38 (7) 3 (5) 22 (9) 38 (12) 
Therapeutic range (INR) 
 Low (2.0-3.5)  1033 (89) 463 (88) 53 (87) 222 (88) 295 (93) 
 High (2.5-4.0) 124 (11) 63 (12) 8 (13) 31 (12) 22 (7) 
Anticoagulant 
 Phenprocoumon  972 (84) 435 (83) 49 (80) 221 (87) 267(84) 
 Acenocoumarol 162 (14) 77 (15) 10 (16) 29 (12) 46(15) 
 Warfarin  23 (2) 14 (3) 2 (3) 3 (1) 4 (1) 
Comorbidity score 
 0 421 (48) 252 (48) 31 (51) 120 (47) 18 (50)* 
 1 234 (27) 140 (27) 16 (26) 67 (27) 11 (31)* 
 2 126 (14) 71 (14) 9 (15) 41 (16) 5 (14)* 
 3 47 (5) 31 (6) 1 (2) 14 (6) 1 (3)* 
 4+ 48 (5) 32 (6) 4 (7) 11 (4) 1 (3)* 
 
Baseline characteristics at the time of reaching stable anticoagulation are 
displayed in Table 1. A total of 872 patients returned the questionnaire 
(75%) of which 840 (73% of total) included a valid FFQ. Of those, usual 
vitamin K intake was normal in 63% of patients, low in 7% and high in 
30% of patients. Patients with a low vitamin K intake were slightly more 
often < 50 years of age and female than those with a normal intake. There 
were no major differences in indication for anticoagulant treatment, 
therapeutic range, use of anticoagulant drug and comorbidity. 
The total follow-up time was 313 person-years (average 99 d). Of the 
1 157 patients, 335 had a subtherapeutic INR during follow-up. Ninety-two 
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of those patients had stopped their anticoagulant drug or had been given 
vitamin K and were censored in the analysis. At 8 weeks 14% of patients 
had had a low INR and at 16 weeks this was 23%. Figure 2 shows the 
Kaplan Meier-curve of the probability of a subtherapeutic INR for the 
different vitamin K intake categories. Compared to patients with a normal 
usual vitamin K intake, those with a high vitamin K intake had a slightly 
lower risk of a subtherapeutic INR (Hazard Ratio [HR] 0.80, 95% 
confidence interval [95%CI]: 0.56-1.16) and those with a low vitamin K 
intake had a higher risk (HR 1.33, 95%CI: 0.79-2.25). Compared to patients 
with a high vitamin K intake, patients with a low vitamin K intake had a 
1.66-fold increased risk (95%CI: 0.93-2.96). Adjustment for age, sex and 
comorbidity score did not change the results (HR 0.81, 95%CI: 0.56-1.17 
for high vitamin K intake and HR 1.26, 95%CI: 0.74-2.14 for low vitamin K 
intake). The association between vitamin K intake and the risk of a 
subtherapeutic INR showed a dose effect relationship (P value for the log 
rank test for trend = 0.08). 
 
Figure 2. Kaplan Meier curve of the probability of a subtherapeutic INR according to usual vitamin K intake 
category. In the table, values are expressed as the number of patients at risk (number with a subtherapeutic INR)  
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Table 2: Difference of recent vitamin K intake between cases and controls, compared 
between low, normal and high usual vitamin K intake categories. * adjusted for sex, age 
category, season of vitamin K intake measurement and duration of follow-up 
Recent vitamin K intake  
(µg/24 hrs (n)) 
Usual vitamin 
intake 
category Controls Cases  
Difference 
(95%CI) 
Adjusted difference* 
(95%CI) 
Low  85  (15)  164  (7)  80  (-32 to 191)  87  (-39 to 214) 
Normal  199  (103)  192  (39)  -6  (-69 to   56)  -7  (-72 to   57) 
High  309  (36)  292  (9)  -17 (-192 to 158)  -10 (-172 to 153) 
Missing  137  (34)  233  (8)  95  (-45 to 236)  91  (-58 to 240) 
All  200  (188)  208  (63)  9  (-45 to   62)  12  (-41 to   66) 
 
 
 
Of the 335 patients who had a subtherapeutic INR, 194 were contacted 
by telephone for the nested case control study. Of these, 53 patients did not 
answer the telephone, 16 patients refused to participate and 28 had other 
reasons why they were ineligible (incorrect telephone number, nursing 
home residents, dementia, hearing impairment). Ninety-seven patients 
completed the interview, of whom 90 were able to give a valid dietary recall. 
Of these 90 patients, 27 patients had stopped their anticoagulant drug or 
had been given vitamin K and were excluded from the study. Of the 340 
control patients who were selected 195 completed the interview and 188 
patients gave a valid dietary recall, 98 patients did not answer their 
telephone, 19 refused and 28 had other reasons not to participate. 
Table 2 shows the average recent vitamin K intake for cases and 
controls, categorized by usual vitamin K intake. In control patients recent 
vitamin K intake was in agreement with usual vitamin K intake. There was 
no difference in recent vitamin K intake between cases and controls overall: 
Average intake was 200 µg in control patients and 208 µg in cases 
(difference 9 µg, 95%CI: -45 to 62). However, in individuals with a low 
usual vitamin K intake, recent vitamin K intake was twice as high in patients 
with a subtherapeutic INR as in controls, with a difference of 80 µg 
(95%CI: −32 to 191). A similar difference was observed in patients who had 
not completed the FFQ.  
Table 3 shows odds ratios for a normal recent vitamin K intake (higher 
than 100 µg/d) versus a low recent vitamin K intake (lower than 100 µg/d), 
again separately for individuals with a low, normal or high usual vitamin K 
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intake. In patients with a low usual vitamin K intake, 43% (3 out of 7) of 
cases had a recent intake of more than 100 µg/d, versus 20% (3 out of 15) 
in controls (OR 3.0, 95%CI: 0.4-21.3), indicating that those individuals who 
usually take low amounts of vitamin K had a threefold increased risk of a 
subtherapeutic INR when they increased their vitamin K intake above 
100 µg/d in comparison to when their vitamin K intake stayed below 
100 µg/d. This increase in risk was not present in individuals with a normal 
or high usual vitamin K intake. 
 
Table 3: Odds Ratios for the risk of a subtherapeutic INR for normal (higher than 
100 µg/d) versus low (lower than 100 µg/d) recent vitamin K intake, categorized per usual 
vitamin K intake group. 
 No patients (%)  
Usual vitamin K 
intake 
Recent vitamin K 
intake Cases Controls OR (95%CI) 
Low Normal 3 (43) 3 (20)  3.0 (0.4-21.3) 
 Low 4 (57) 12 (80)  
Normal Normal 21 (54) 58 (56)  0.9  (0.4-  1.9) 
 Low 18 (46) 45 (44)  
High Normal 7 (78) 29 (81)  0.8  (0.1-  5.0) 
 Low 2 (22) 7 (19)  
All Normal 35 (56) 102 (54)  1.1  (0.6-  1.9) 
 Low 28 (44) 86 (46)  
 
Discussion 
We followed 1 157 patients in a routine setting of a Dutch anticoagulation 
clinic. A 20% decrease was found in the risk of a subtherapeutic INR in 
patients with a high vitamin K intake and a 33% increase in patients with a 
low dietary vitamin K intake. While there was no difference in recent 
vitamin K intake between cases and controls in individuals with a normal or 
high usual vitamin K intake, patients with a low usual vitamin K intake 
consumed twice as much vitamin K in the 48 hours prior to a 
subtherapeutic INR. Our results suggest that a high vitamin K intake 
reduces the risk of low INR values by lessening the influence of incidental 
consumption of vitamin K rich food on the INR. This finding is important 
because it may contradict conventional dietary recommendations for 
patients using vitamin K antagonists. 
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There are currently several recommendations regarding vitamin K 
intake for patients using oral anticoagulants. These include keeping vitamin 
K intake constant,20;21 limiting or even avoiding intake of foods high in 
vitamin K,22 and consuming sufficient vitamin K to meet the adequate 
intake (AI).23 The first recommendation, to keep the vitamin K intake 
constant, can be justified by findings of changes in vitamin K intake 
resulting in both under- and overanticoagulation.9;14 However, because 
different food items vary greatly in vitamin K content, keeping vitamin K 
intake constant is unfeasible, even for the most motivated patients. Daily 
vitamin K intake ranges from <10 to >2500 µg/d, and the intraindividual 
variability is much higher than the interindividual variability.24 Limiting or 
avoiding foods high in vitamin K reduces total vitamin K intake and will, 
according to our data, increase the risk of a subtherapeutic INR. Our results 
support the third recommendation, to consume sufficient vitamin K to 
meet the adequate intake.  
Our results are in concordance with the finding that vitamin K is lower 
in unstable patients than in stable patients, indicating that a low vitamin K 
intake is a risk factor for unstable anticoagulation.10 The recommendation to 
consume sufficient vitamin K rich food is also supported by evidence that 
controlled, low-dose vitamin K supplementation increases stability of 
anticoagulation.25;26 While we found a relation between dietary intake and 
low INRs, the relation between low vitamin K intake and over-
anticoagulation is unclear, with one study reporting no relation.16 It would 
be worthwhile to investigate the effect of low vitamin K intake on the 
incidence of over-anticoagulation. 
Genetic variants of VKORC1, the gene encoding the target enzyme for 
vitamin K antagonists, have been shown to contribute importantly to the 
differences in sensitivity to vitamin K antagonists.27 Compared to the wild 
type, the G1639A polymorphism results in less VKORC1 enzyme, so that a 
lower dose of VKA is needed to achieve the same anticoagulant effect. 
There have been some studies on the effect of VKORC1 genotype on 
stability of anticoagulation,28-30 but at this moment it is not known whether 
changes in dietary vitamin K intake have a bigger influence on the stability 
of anticoagulant therapy in patients with the G1639A variant although one 
would assume that this is the case. In this regard it is also possible that the 
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improvement of anticoagulant control that been observed in patients 
supplemented with a low dose of vitamin K depends on the VKORC1 
polymorphism. The effect of VKOR genotype on stability of anticoagulant 
therapy in relation to dietary vitamin K intake needs to be investigated in 
more detail. 
We chose to develop the FFQ and the dietary recall instead of using 
existing questionnaires. This has both advantages and disadvantages. 
Advantages are that the questionnaires were developed specifically to 
measure vitamin K intake and that they were directed to the studied 
population by including food items contributing most to vitamin K intake 
in the Dutch population. This is important because typical Dutch food 
includes many vitamin K-rich foods such as curly kale and sauerkraut. A 
disadvantage is that the questionnaires have not been validated. However, 
there was a correlation between the FFQ and the dietary recall 
questionnaire, providing a relative validation. A more general problem with 
measuring dietary vitamin K intake is the substantial difference in the 
reported vitamin K content of foods analyzed in different laboratories.31 
Because any resulting misclassification does not depend on whether or not 
people experience low INRs the reported results are likely to be an 
underestimation of the effect. 
Even though we followed a large cohort of 1 157 patients, the number 
of events in the subgroups of patients with low or high usual vitamin K 
intake was relatively small and thus the confidence intervals were wide. 
However, considering that our results are in agreement with other studies 
investigating the role of dietary vitamin K intake in anticoagulant 
stability,10;25;26 and considering that our results show a dose effect 
relationship, they contribute to the growing body of evidence that patients 
on vitamin K antagonists should receive the same dietary advice as the rest 
of the population: Maintain a healthy diet containing sufficient fruits and 
vegetables. 
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Until recently, the view that dietary vitamin K interferes with oral 
anticoagulant therapy was based on case reports and a few small 
experimental studies with extremely high vitamin K intake. In two recent 
studies the effect of dietary vitamin K on oral anticoagulation was 
systematically investigated.1;2 These studies showed that even in patients on 
an average diet changes in vitamin K intake affect anticoagulation. When 
patients decreased their vitamin K intake the response on the International 
Normalized Ratio (INR) was more pronounced than when vitamin K intake 
was increased2. Because changes are proportionally larger in people with a 
low average vitamin K intake, it is likely that the INR is more sensitive to a 
varying vitamin K intake in those individuals. Sconce et al. established that 
daily intake of vitamin K was indeed lower in patients with unstable 
anticoagulation than in stably anticoagulated patients.3 Daily 
supplementation of low doses of vitamin K might thus be beneficial.  
To safely start vitamin K supplementation in patients receiving oral 
anticoagulants, it is important to know the effect of low doses of vitamin K 
on the INR and on the dose of the anticoagulant drug. The dose-response 
relationship of vitamin K supplementation on the INR in healthy subjects 
that received a fixed dose of oral anticoagulants was established by 
Schurgers et al.4 They concluded that 100 µg of vitamin K daily did not 
significantly interfere with oral anticoagulant therapy. Consequently, 
Oldenburg suggested 100 µg vitamin K as a recommended supplementation 
dose in his editorial.5 However, Kurnik et al. found that in patients with a 
low vitamin K status even daily supplement doses as low as 25 µg led to an 
important reduction of the INR.6 
We performed a pilot study to determine the effect of escalating daily 
doses of vitamin K on the required dose of the anticoagulant drug 
phenprocoumon. We included patients from the Leiden Anticoagulation 
Clinic that took part in a program for self-management of anticoagulant 
treatment. The total study period was 9 weeks, in which the INR was 
measured at least 3 times a week with a CoaguCheck S coagulometer 
(Roche Diagnostics, Almere, Netherlands). Patients received vitamin K for 
3 weeks. The first and last 3 weeks served as control periods. Five patients 
received 50 µg and 10 patients 100 µg of oil-based vitamin K1 (250 µg/g). 
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The primary endpoint was the percentage change in phenprocoumon dose 
during and after vitamin K needed to keep the INR within therapeutic 
limits. 
Supplementation of 50 µg vitamin K had little effect on the INR and 
therefore only slight dose-adjustments were made (mean dose increase after 
starting vitamin K 3% (95% confidence interval (95%CI): -4% to 10%). 
Supplementation of 100 µg resulted in a mean dose increase of 9% (95%CI: 
0% to 19%, figure 1). There was considerable inter-individual variability in 
response with dose-adjustments ranging from -7% to 37%. In the three 
weeks follow-up after the vitamin K was discontinued phenprocoumon 
doses were lowered to pre-substitution values (mean change of -7%, 
95%CI: -15% to 0%).  
Our results show that daily supplementation up to 100 µg can be given 
without a relevant decrease in the INR, on the condition of frequent 
monitoring during and after the supplementation to allow timely dose 
adjustments. 
 
 
 
 
 
Figure 1: Effect of vitamin K supplementation on the mean International Normalized 
Ratio (INR) (•) and the mean phenprocoumon dose () in 10 patients receiving 100 µg 
vitamin K daily.  
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Abstract 
Background 
One of the causes of unstable anticoagulant control in patients using 
vitamin K antagonists is a fluctuating intake of vitamin K. Research 
suggests that patients with a low dietary intake of vitamin K have a less 
stable anticoagulant control than patients with a higher intake.  
Objectives 
To study whether supplementation with a low daily dose of vitamin K 
improves anticoagulant control. 
Methods 
We performed a double blind, randomized, placebo controlled trial. Two 
hundred patients of the Leiden anticoagulation clinic, who used the 
vitamin K antagonist phenprocoumon were randomized to receive either 
adjusted-dose phenprocoumon and 100 µg vitamin K once daily or 
adjusted-dose phenprocoumon and a placebo. Treatment duration was 24 
weeks. The primary outcome was the percentage of time the INR was 
within the therapeutic range. 
Results 
Time in therapeutic range was 85.5% in the placebo group and 89.5% in the 
vitamin K group (adjusted difference 3.6%, 95% confidence interval 
[95%CI]: -0.8% to 8.0%). Time below the therapeutic range was 3.1% in the 
placebo group and 2.1% in the vitamin K group (adjusted difference -0.7 %, 
95%CI: -2.5% to 1.1%) and time above the therapeutic range was 11.4% in 
the placebo group and 8.5% in the vitamin K group (adjusted difference 
-2.9%, 95%CI: -6.9% to 1.1%).  
Conclusion 
Supplementation of vitamin K antagonists with 100 µg vitamin K improves 
stability of anticoagulant therapy. Because the risk of side effects is inversely 
related to anticoagulant stability, such an improvement is likely to reduce 
the number of bleeding and thrombotic events. 
 
  53 
Introduction 
Oral anticoagulant treatment with vitamin K antagonists is indicated for the 
primary and secondary prevention of both arterial and venous thrombosis.1 
A major disadvantage of vitamin K antagonists is their narrow therapeutic 
window and the large inter- and intra-individual variability in anticoagulant 
response. Despite intensive monitoring the intensity of anticoagulation, 
expressed as the International Normalized Ratio (INR), is within the target 
range only approximately 60% of the time.2 The impact of under- and 
overanticoagulation is high, with a sharp increase of severe hemorrhage 
when the INR rises above the therapeutic range and a rise in thrombotic 
risk as the INR falls below the therapeutic range.2-4 Improvement of the 
quality of anticoagulant treatment will reduce the number of these adverse 
events.  
One of the causes of the variability in anticoagulant response is a 
fluctuating vitamin K intake.5;6 Studies have shown that the INR is 
especially sensitive to vitamin K changes when vitamin K intake is low.6;7 In 
patients with unstable anticoagulant control daily intake of vitamin K has 
been shown to be lower than in stably anticoagulated patients.8 We 
hypothesized that supplementation with a low daily dose of vitamin K 
results in increased stability of anticoagulant control. The objective of this 
study was to test this hypothesis clinically, by assessing the effect of 
vitamin K supplementation on anticoagulant stability in patients treated 
with vitamin K antagonists. 
 
Methods 
Study design 
The study was a double blind, randomized, placebo controlled trial. Two 
hundred patients were randomized in blocks of 8 patients into two equal 
groups. All patients were treated with adjusted-dose phenprocoumon, a 
vitamin K antagonist with a long half-life of 140 hours. In addition, patients 
in the treatment group received 100 µg vitamin K once daily, patients in the 
other group a placebo once daily. The study medication was used for 24 
weeks. After this patients were followed for an additional 4 weeks, to 
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observe possible side effects after stopping the study medication. The study 
was approved by the local Medical Ethics Committee. Written informed 
consent was obtained from all participants prior to enrolment.  
 
Participants 
Participants were recruited from the Leiden anticoagulation clinic. Patients 
were considered for enrolment if they were between 18 and 80 years of age, 
had an indication for long-term oral anticoagulant therapy and had been 
using phenprocoumon for at least one year. Exclusion criteria were: 
treatment by a medical specialist for liver failure; haemo- or peritoneal 
dialysis; pregnancy or planned pregnancy; puerperium; any chronic 
condition with an expected survival of less than 6 months; an expected 
interruption of oral anticoagulant treatment of more than one week; self-
management of oral anticoagulant treatment and non-compliance, based on 
information from the anticoagulation clinic computer records.   
The required sample size was calculated using data of the Leiden 
anticoagulation clinic. We expected an improvement of the time in 
therapeutic zone from 75% to 85%. The standard deviation of the time in 
therapeutic zone was estimated at 23%. To achieve 80% power for 
detecting this difference at a significance level of 5%, 84 subjects per group 
were required. Allowing for a loss of patients of 15% the total number of 
patients was rounded to 200. 
 
Procedures 
The study was performed at the Leiden anticoagulation clinic, where 
approximately 7 000 patients are treated each year. During the first four 
weeks after starting the study medication the INR was measured weekly to 
be able to adjust the dosage of phenprocoumon in case of INR changes due 
to the vitamin K.  Subsequently, the interval between visits depended on 
anticoagulant stability, with a maximum of 4 weeks. After stopping the 
study medication patients were again seen at weekly intervals for four 
weeks. INR results and prescribed dosages were recorded in a central 
database, along with relevant history details, changes in medication, 
information on bleeding and thrombotic complications, admissions and 
surgical interventions. After inclusion patients were asked to list their 
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current co-medications. No specific dietary recommendations were given. 
Compliance with the study medication was verified by pill-counting. We 
classified patients as compliant when they had used over 90% of the 
prescribed capsules, non-compliant otherwise. 
The therapeutic ranges were according to the guidelines of the 
Federation of Dutch Anticoagulation Clinics: INR 2.0-3.5 with a target INR 
3.0 for low intensity treatment and INR 2.5-4.0, target INR 3.5 for high 
intensity treatment.  
Capsules containing 100 µg of vitamin K or placebo were manufactured 
by Numard Pharmaceuticals (Lelystad, The Netherlands) from 5% dry 
vitamin K (Acatris, Londerzeel, Belgium). The dose of 100 µg vitamin K 
was chosen because of the results of a pilot study, in which we found that 
this dose had only a minor effect on the INR and subsequent dosage 
adjustments, while being close to the recommended daily intake (90 µg for 
women, 120 for men9).10 
 
Data analysis 
The primary study outcome was the quality of anticoagulant treatment, 
expressed as percentage of time of the INR in the therapeutic range. Time 
in range was calculated with the linear interpolation method, as described by 
Rosendaal11. In this method, the INR is modeled to increase or decrease 
linearly between two consecutive measurements. Each time period between 
two INR measurements can then be divided into time in, above or below 
the therapeutic range. For each patient time per category is summed and 
divided by the total follow-up time. Because the research question was 
mechanistic rather than a question of efficacy, we only calculated the time in 
range over the period the study medication was used. Also, the first four 
weeks after starting the study-medication were excluded from the analysis, 
to allow some time to find a new dose balance. Secondary outcome 
measures were the number of bleeding and thrombotic complications. 
Major hemorrhage was defined as fatal or intracranial hemorrhage and any 
hemorrhage that required blood transfusion, hospitalization or surgery, as 
well as muscle and joint bleeding.  
Finally, we classified patients in categories of stability and contrasted 
patients with maximal stability (time in range of 100% during follow-up) 
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between the treatment and placebo group, which allowed the calculation of 
a relative risk. 
Age, sex, target-range, use of co-medication and use of medication 
interacting with the anticoagulant drug were considered possible 
confounders and were adjusted for in the analysis.  
 
Results 
Patients were enrolled between December 2004 and January 2006 
(Figure 1). Of 1 053 patients, 200 consented to be randomized. Data on 18 
patients were not or only partly analyzed, because they did not complete 
follow-up. Follow-up time was 34.2 patient-years (py) in the placebo-group 
and 33.7 py in the vitamin K group.  
 
 
 
 
 
Figure 1: Flow of patients through the trial 
1053 
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1011 
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100 Vitamin K 
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 192 could not be contacted 
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(number INRs <3) 
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(number INRs <3) 
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1 died 
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Table 1: Baseline characteristics of the study population. Data are median (interquartile 
range) or number (%) 
  Placebo 
(n = 95) 
Vitamin K 
(n = 94) 
Age 68  (59-73) 65  (60-73) 
Female sex (%) 27  (28%) 20  (21%) 
Duration of anticoagulant treatment (years) 4  (2-9) 4  (2-7) 
Previous stability (time in therapeutic range) 80% (74%-84%) 79% (72%-84%) 
Indication (%)   
 Atrial fibrillation 38  (40%) 40  (43%) 
 Secondary prevention venous thrombosis  12  (13%) 15  (16%) 
 Mechanical heart valve 12  (13%) 9  (10%) 
 Other arterial 33  (35%) 30  (32%) 
Therapeutic range (%)   
 Low (2.0 - 3.5) 51  (54%) 57  (61%) 
 High (2.5 - 4.0) 44  (46%) 37  (39%) 
Number of comedications 4  (2-6) 3  (2-5) 
Interacting medication (%)   
 No 50  (53%) 62  (66%) 
 Yes 45  (47%) 32  (34%) 
 
Patient characteristics are shown in Table 1. Age, sex, duration of 
anticoagulant treatment, previous stability and indication for anticoagulant 
treatment were similar in both groups. In the placebo group were slightly 
more patients in the high target range. Patients in the placebo group used 
more co-medications, including drugs interacting with anticoagulants. 
The primary study outcome is shown in Table 2. Time in therapeutic 
range was 85.5% in the placebo group (95% confidence interval [95%CI]: 
82.3% to 88.6%) and 89.5% in the vitamin K group (95%CI: 86.4% to 
92.5%). Time in range was 4.0% higher in the vitamin K group than in the 
 
Table 2: Time in -, below - and above the therapeutic range. Data provided are mean 
percentages (95%CI) of time in, below and above the therapeutic range. * Adjusted for age, 
sex, target range, number of co-medications and use of interacting medication. 
  
Placebo 
(n = 95) 
Vitamin K 
(n = 94) Difference 
Adjusted 
difference* 
Time in  
therapeutic range  
85.5   
(82.3 to 88.6) 
89.5  
(86.4 to 92.5) 
4.0  
(-0.3 to 8.3) 
3.6  
(-0.8 to 8.0) 
Time below therapeutic 
range  
 3.1  
(1.6 to 4.5) 
2.1  
(1.0 to 3.1) 
-1.0  
(-2.8 to 0.7) 
-0.7  
(-2.5 to 1.1) 
Time above therapeutic 
range  
11.4  
(8.5 to 14.4) 
8.5  
(5.8 to 11.1) 
-3.0  
(-6.9 to 0.9) 
-2.9  
(-6.9 to 1.1) 
 
  58 
placebo group (95%CI: -0.3% to 8.3%). After adjusting for age, sex, target 
range, number of co-medications and use of interacting medication this 
difference was 3.6% (95%CI: -0.8 to 8.0). Both time below the therapeutic 
range and time above the therapeutic range were slightly lower in the 
vitamin K group.  
Figure 2 shows the percentage of patients classified in categories of 
time in therapeutic range. Of the patients in the vitamin K group 43% were 
in the therapeutic range 100% of the time versus 24% in the placebo group. 
The relative risk of a maximal stability in the vitamin K group compared to 
placebo was 1.8 (95%CI: 1.1 to 2.7).  
Table 3 shows the time in therapeutic range in the vitamin K and the 
placebo group for different patient and treatment characteristics. The 
results are similar for all categories. Patients in the vitamin K group were 
more stable in all but three subgroups, although confidence intervals are 
wide. Previous stability was the best predictor of time in therapeutic range 
during the trial.  
 
 
 
Figure 2: Percentage of patients in categories of time in therapeutic range 
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Table 3: Percentage of time in the therapeutic range in various patient categories. Data 
provided are mean percentages (95%CI) of time in the therapeutic range 
  Placebo group  
(n = 95) 
Vitamin K group  
(n = 94) 
 
  
number 
of 
patients 
percentage 
time in the 
therapeutic 
range 
number 
of 
patients 
percentage 
time in the 
therapeutic 
range  Difference 
Age      
 <60y 29 85 (79-91) 27 89 (83-94)  3.7 (-4.3 to 11.7) 
 60-70 32 88 (83-93) 34 90 (85-96)  2.5 (-5.0 to 10.0) 
 70-80 34 84 (78-89) 33 89 (84-94)  5.6 (-1.9 to 13.1) 
Sex      
 Male 68 85 (81-89) 74 90 (86-93)  4.5 (-0.6 to 9.6) 
 Female 27 86 (81-91) 20 89 (81-97)  2.6 (-6.2 to 11.4) 
Duration of anticoagulant treatment (years) 
 <=2y 26 84 (77-91) 26 82 (74-91)  -1.5 (-11.9 to 8.7) 
 2-4y 23 83 (75-90) 24 93 (89-97)  10.0 (2.0 to 17.9) 
 4-6y 12 84 (75-93) 18 92 (84-99)  7.5 (-3.6 to 18.6) 
 >6y 34 89 (84-93) 26 92 (88-97)  3.1 (-3.4 to 9.6) 
Previous stability (time in therapeutic range) 
 <60% 4 68 (41-96) 5 74 (41-107)  5.8 (-30.5 to 42.2) 
 60-80 48 87 (83-91) 48 87 (82-91)  0.1 (-5.9 to 6.1) 
 80-100 43 86 (81-91) 41 95 (91-98)  8.8 (3.1 to 14.6) 
Indication      
 Atrial fibrillation 38 84 (78-89) 40 88 (83-94)  4.6 (-3.2 to 12.5) 
 Secondary prevention 
venous thrombosis  
11 81 (69-94) 15 93 (86-99)  11.5 (-0.7 to 23.7) 
 Mechanical heart valve 12 87 (78-96) 9 92 (84-99)  5.0 (-6.5 to 16.6) 
 Other arterial 33 88 (84-93) 30 89 (84-94)  0.4 (-6.3 to 7.0) 
Therapeutic range      
 Low (2.0 - 3.5) 51 84 (79-89) 57 90 (85-94)  5.9 (-0.4 to 12.2) 
 High (2.5 - 4.0) 44 87 (83-91) 37 89 (85-93)  1.7 (-4.1 to 7.4) 
Compliance study 
medication 
     
 Compliant 77 88 (85-91) 73 90 (87-93)  2.2 (-2.3 to 6.7) 
 Noncompliant 3 69 (26-112) 5 82 (56-107)  13.0 (-21.8 to 47.8) 
 Not counted 15 78 (67-88) 16 90 (82-99)  12.6 (-0.4 to 25.7) 
Dose adjustment      
 < -5% 20 82 (74-89) 7 78 (64-92)  -3.8 (-18.5 to 10.9) 
 -5% to 5% 55 86 (82-91) 35 93 (89-97)  6.6 (-0.2 to 12.9) 
 >5% 20 87 (82-93) 52 89 (84-93)  1.6 (-6.1 to 9.3) 
Number of comedications     
 0-2 33 85 (80-91) 42 92 (88-97)  7.2 (0.4 to 13.9) 
 3-5 38 85 (79-91) 39 88 (83-93)  3.1 (-4.1 to 10.2) 
 >=6 24 86 (81-92) 13 84 (73-95)  -2.3 (-12.7 to 8.1) 
Interacting medication      
 No 50 86 (81-90) 62 91 (88-95)  5.6 (0.2 to 11.1) 
 Yes 45 85 (80-90) 32 86 (81-92)  0.8 (-6.5 to 8.1) 
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Compared to the 24 weeks before the start of the study medication, the 
dose was increased by an average of 0.8% in the placebo group (range -16% 
to 57%) and 7.0% in the vitamin K group (range -57% to 39%). The 
difference in time in range between the placebo group and the vitamin K 
group was largest in patients with a dose change between -5% and 5% 
(Table 3).  
Three patients in the placebo group and 5 in the vitamin K group were 
classified as noncompliant with the study medication (more than 10% of 
the prescribed capsules not taken). Both compliant and noncompliant 
patients were more stable in the vitamin K group than in the placebo group 
(Table 3).  
The beneficial effect of vitamin K was strongest (7.2% time in range) in 
those with no or few co-medications and absent in those with 6 or more co-
medications. When we looked specifically at drugs that potentially interact 
with vitamin K antagonists, we found that the effect of vitamin K 
supplementation appeared restricted to those who did not use interacting 
agents (Table 3). 
Two patients died, one in the vitamin K group (intracranial hemorrhage 
due to cerebral contusion) and one in the placebo group (cause of death 
unknown). Two patients in the vitamin K group had a major bleeding 
event; the before-mentioned fatal bleed (last known INR 2.8) and a 
muscular bleed (INR 5.1). There were 17 minor bleeding episodes, 10 in the 
placebo and 7 in the vitamin K group (relative risk [RR] for any bleeding 
event, vitamin K group versus placebo group: 0.9, 95%CI: 0.3 to 2.3). No 
thrombotic events were reported. There were five self-reported putative 
side effects, four of which in the placebo group. These included weight gain 
(two patients in the placebo group, one in the vitamin K group), flatulence 
and indigestion.  
 
Discussion 
We performed a randomized placebo-controlled trial in 200 outpatients of a 
Dutch anticoagulation clinic, to study the effect of vitamin K 
supplementation in patients treated with oral anticoagulants. We observed a 
small increase in stability of anticoagulant treatment in patients receiving 
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vitamin K supplementation. There was a two-fold increase in the 
percentage of patients with a maximal stability of 100% of time within the 
therapeutic range, from 24% to 43% of patients.  
The need to investigate whether vitamin K supplementation leads to an 
improved anticoagulant stability has been identified by several authors.12;13 
The question was raised based on recent studies that showed that the INR 
is more sensitive to vitamin K changes in patients with a low vitamin K 
status than in those with a normal or high vitamin K status6;7 and that 
dietary vitamin K intake in unstable patients is considerably lower than in 
stable patients.8 Recently, Sconce et al. published their results of a study 
investigating vitamin K supplementation in 70 patients receiving warfarin 
with an unstable anticoagulant control.14 They found that supplementation 
with 150 µg of vitamin K increased stability of anticoagulation, expressed as 
the standard deviation of the INR and the percentage of time in the target 
range. Our results confirm that this strategy increases the time in 
therapeutic range in an unselected population of patients using vitamin K 
antagonists. 
The observed improvement in time in therapeutic range of 4% was 
smaller than the improvement of 10% on which the study was powered. 
This explains why the results do not reach the significance level of 5%: the 
size of our study was too small to detect this smaller difference. Taking into 
consideration the biologic plausibility of the results, previous studies 
showing low vitamin K status in unstable patients and the previous trial by 
Sconce et al.,14 we believe that the observed difference is real. The key 
question of course is whether this difference is clinically relevant. The 4% 
improvement of time in therapeutic range will theoretically prevent 1-2 
serious side effects per 1 000 treatment-years.2 It must be kept in mind that 
time in therapeutic range in this study improved from 85% to 89%. So, 
even in the placebo group time in range was unexpectedly high. In a less 
stable population, the benefit of vitamin K supplementation is likely to be 
higher than the observed 4% difference.  
There are several reasons why time in therapeutic range was higher in 
this study than is usually reported. One reason is the definition of 
therapeutic range, which is wider in the Netherlands than in other countries, 
where a target range of 2.0-3.0 is frequently employed. Furthermore, only 
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patients who had been using anticoagulants for more than a year were 
included. These patients are often more stable than short-term patients. 
Finally, even in the placebo group time in range was 7% higher than before 
the trial. There are two possibilities why the time in the therapeutic range 
was so high in the placebo group: Firstly, the study population (placebo and 
treatment group) differed from the routinely treated patients. This is a 
common phenomenon in randomized trials, due to exclusion criteria, self-
selection of consenting patients or because patients changed their behaviour 
during the trial. Another possibility is that  the placebo group differed from 
the treatment group by chance. If this were the case, the true effect was 
seemingly reduced, and in fact higher.  
Despite randomization the groups differed in use of co-medication. 
Patients in the placebo group used more co-medications in general and also 
more drugs interacting with vitamin K antagonists. Because time in 
therapeutic range was associated with both variables, they were adjusted for 
in the analysis. An interesting finding was that vitamin K supplementation 
especially improved anticoagulant control in patients using no or few co-
medications and in patients not using interacting medication. However, 
because this was a post-hoc subgroup analysis with wide confidence 
intervals, these results should be interpreted with caution.   
A theoretical concern is that increasing the dose of the vitamin K 
antagonist increases the risk of side-effects unrelated to the INR. Other 
proteins than those involved in haemostasis depend on the enzyme system 
affected by vitamin K antagonists.15 However, in the past decades of oral 
anticoagulant use, the number of reported side-effects other than 
haemorrhage has been remarkably low. 
A limitation of this study was that blinding may not have been 
completely maintained because of dose adjustments in the treatment group. 
Because patients in the vitamin K group did better when there were no 
large dose adjustments, it is unlikely that this affected the results.  
Oral anticoagulants are among the most frequently prescribed drugs. In 
Western countries they are used by over 1% of the adult population.16;17 Ten 
percent of hospital admissions due to adverse drug events are caused by 
oral anticoagulants, often as a result of overanticoagulation.18 Improvement 
of the quality of oral anticoagulant therapy will result in less thrombosis and 
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fewer bleeding events and thus in a major reduction of burden of disease. 
Our results show that supplementation with a low dose of oral vitamin K 
contributes to improved anticoagulant stability. Further research on the 
optimal dosage of vitamin K supplementation in various patients groups is 
necessary to optimize anticoagulant control. 
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Abstract 
Background 
Vitamin K supplementation improves anticoagulant stability in patients 
using vitamin K antagonists. 
Objectives 
To determine whether there is an association between vitamin K status and 
stability of anticoagulant treatment. 
Methods 
We examined the relationship between vitamin K1 and its metabolite, 
vitamin K 2,3-epoxide and stability of oral anticoagulant treatment in 
participants of a double-blind, placebo-controlled trial on the effect of 
vitamin K supplementation on anticoagulant stability. Vitamin K1 and 
vitamin K 2,3-epoxide serum levels were determined in 91 patients 
receiving placebo and 91 patients receiving 100 µg vitamin K per day. The 
effect of these variables on time in therapeutic range (TTR) was assessed 
using linear regression analysis. 
Results 
In the placebo group each standard deviation (SD) increase in vitamin K1 
level was associated with a 3.4% higher TTR. Vitamin K 2,3-epoxide levels 
increased the TTR with 2.7% per SD, but this effect disappeared when 
vitamin K1 and vitamin K 2,3-epoxide levels were combined in one model. 
In the group receiving the vitamin K supplement we found no effect of 
vitamin K status on the TTR. 
Conclusion 
These findings contribute to the evidence that an adequate intake of 
vitamin K can improve anticoagulant control. 
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Introduction 
Vitamin K antagonists are indicated for the prevention of venous and 
arterial thrombosis.1 Even though their effectiveness has been well 
established, many patients are denied the benefits of these drugs due to the 
difficulty in maintaining stable anticoagulation.2 Vitamin K antagonists have 
a narrow therapeutic window and a high variability in anticoagulant 
response. Despite intensive monitoring, the intensity of anticoagulation, 
expressed as the International Normalized Ratio (INR), is within the target 
range only approximately 60% of the time.3 
One of the causes of a fluctuating INR is a variable vitamin K intake. 
Vitamin K in its reduced form (vitamin K hydroquinone) is an essential 
cofactor for the posttranslational carboxylation of various proteins involved 
in blood coagulation, among which the procoagulant factors II, VII, IX and 
X. During the carboxylation reaction, the vitamin K hydroquinone is 
converted to its inactive metabolite, vitamin K epoxide, which is 
subsequently converted back to vitamin K hydroquinone by vitamin K 
epoxide reductase (VKOR). Vitamin K antagonists inhibit VKOR, thereby 
blocking the turnover of vitamin K epoxide resulting in depletion of the 
active vitamin K stores. This leads to the desired anticoagulant effect due to 
reduced production of fully carboxylated vitamin-K dependent clotting 
factors.4 
Previous studies have suggested that patients with a low vitamin K 
intake have a less stable anticoagulation than patients with a higher intake.5-8 
Supplementation with low doses of vitamin K has been shown to improve 
anticoagulant stability.9;10 This can be explained by the hypothesis that the 
INR is relatively resistant to a fluctuating vitamin K intake when average 
vitamin K intake is high. If this hypothesis were true one would also expect 
to find an association between vitamin K status and stability of 
anticoagulation. 
We examined the relationship between serum levels of vitamin K1 and 
its metabolite, vitamin K 2,3-epoxide and stability of oral anticoagulant 
treatment in participants of a clinical trial on the effect of vitamin K 
supplementation on anticoagulant stability. 
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Methods 
We determined the vitamin K status in participants of a randomized 
double-blind placebo-controlled clinical trial on the effect of vitamin K 
supplementation on anticoagulant stability.10 In this trial 200 patients using 
the vitamin K antagonist phenprocoumon were randomized to receive 
either adjusted-dose phenprocoumon and 100 µg vitamin K once daily or 
adjusted dose phenprocoumon and a placebo.  
Participants were recruited from the Leiden anticoagulation clinic in the 
Netherlands. They were between 18 and 80 years of age, had an indication 
for long-term anticoagulant therapy and had been using phenprocoumon 
for at least one year. Patients were enrolled in the study from December 
2004 to January 2006. Treatment duration was 24 weeks. During this time 
patients were treated according to the guidelines of the anticoagulation 
clinic. During the study period the maximum interval between two visits 
was 4 weeks. The primary outcome was the percentage of time the INR was 
within the therapeutic range.10 This study was approved by the local Medical 
Ethics Committee and was registered as an International Standard 
Randomized Controlled Trial, number ISRCTN14473912. 
Eight to twelve weeks after starting the study medication, fasting blood 
samples were obtained by venipuncture. All specimens were kept in the 
dark. Blood samples were processed within 4 hours and aliquots of plasma 
and serum were stored at -80°C. Serum levels of vitamin K1 and vitamin K 
2,3-epoxide were measured by high-performance liquid chromatography 
(HPLC) using zinc postcolumn reduction and fluorescence detection as 
described earlier11;12 with some modifications. In brief, after 
deproteinization of the samples with ethanol  and liquid extraction using 
hexane, solid phase extraction is performed using a 500 mg/3 ml Strata 
C18-M column (Phenomenex, USA). The columns are pretreated with 5 ml 
hexane-2-propanol (98:2) and 5 ml hexane before the addition of the 
sample (2 ml). The vitamin K1 and vitamin K 2,3-epoxide are eluted in a 
total volume of 10 ml hexane and dried under N2 (g) at 40 ºC. The sample is 
taken up in ethanol and injected onto a Lichrospher®100-RP-18 (125-4mm; 
5 µm) column (Merck, Darmstadt, Germany) and eluted at a flow of 1.5 
ml/min using 1M sodiumacetate/acetic acid, 2M Zn Cl2 in methanol (ratio 
  71 
6:1000). A stainless steel column (50-2.1mm) containing zinc particles 
(Vitamin K1  HPLC kit, Immundiagnostic, Bensheim, Germany)  was 
placed between the HPLC column and the fluorimetric detector (model 
FP2020 Jasco, Tokyo, Japan). After the zinc postcolumn reduction the 
separated vitamin K1 and vitamin K 2,3-epoxide were detected at Ex/Em 
of 248/418 nm. 
We used linear regression analysis to assess the association between 
vitamin K1 and vitamin K 2,3-epoxide levels and time in therapeutic range. 
Because both vitamin K1 and vitamin K 2,3-epoxide levels showed a right-
skewed distribution, we log-transformed the data. We then used the 
z-scores of the placebo group as coefficients in the model, so results show 
the change in time in therapeutic range per standard deviation (SD) change 
in serum vitamin K1 or vitamin K 2,3-epoxide. Outliers were identified as 
being greater than the mean ± 3 SD of the logarithm. This resulted in the 
removal of 4 outlier values: 2 patients had a serum vitamin K1 level higher 
than the mean +3 times the SD and 2 patients had a vitamin K 2,3-epoxide 
lower than the mean -3 times the SD. Values were removed rather than 
cases, because in those subjects with extreme values of vitamin K1, 
vitamin K 2,3-epoxide levels were within the mean ± 2 SD and vice versa. 
Furthermore, the INR values of subjects with outliers were within the 
therapeutic range. 
Age, sex, use of co-medication and use of medication interacting with 
the anticoagulant drug were considered potential confounders and were 
adjusted for in the analysis. Analyses were done separately for the placebo 
group and the vitamin K group. All statistical analyses were performed 
using SPSS 17 (SPSS Inc, Chicago, Ill, USA).  
 
Results 
In the 200 patients randomized for the trial, serum vitamin K1 and vitamin 
K 2,3-epoxide serum levels were determined in 91 patients in the vitamin K 
group and 91 patients in the placebo group. For 18 individuals serum or 
assays were unavailable.  
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Table 1: Baseline characteristics of the study population. Data are median (IQR) or 
number (%). 
  Placebo group 
(n = 91) 
Vitamin K group 
(n = 91) 
Age 66 (58-72) 65 (60-74) 
Female sex 26 (29%) 20 (22%) 
Duration of anticoagulant treatment (years) 4 (2-8) 4 (2-8) 
Previous stability (%time in therapeutic range) 80 (73-84) 79 (72-84) 
Indication   
 Atrial fibrillation 38 (42%) 39 (43%) 
 Secondary prevention venous thrombosis  12 (13%) 15 (17%) 
 Mechanical heart valve 12 (13%) 9 (10%) 
 Other arterial 29 (32%) 28 (31%) 
Therapeutic range   
 Low (2.0-3.5) 51 (56%) 56 (62%) 
 High (2.5-4.0) 40 (44%) 35 (38%) 
Number of co-medications 3 (2-5) 3 (1-4) 
Interacting medication   
 No 44 (48%) 55 (60%) 
 Yes 47 (52%) 36 (40%) 
 
 
Patient characteristics are shown in Table 1. Age, sex, duration of 
anticoagulant treatment, previous stability and indication for anticoagulant 
treatment were similar in both groups. In the placebo group there were 
slightly more patients in the high target range. Patients in the placebo group 
used more drugs interacting with anticoagulants. 
Table 2 gives an overview of the vitamin K1 and vitamin K 2,3-epoxide 
levels in the placebo group and the group receiving vitamin K. Mean serum 
vitamin K1 was 0.83 ng/mL in the placebo group and 1.02 ng/mL in the 
vitamin K group (difference 0.20 ng/mL, 95%CI: 0.05 to 0.34). Mean 
vitamin K 2,3-epoxide was 4.60 ng/mL in the placebo group and 7.00 in 
the vitamin K group (difference 2.40 ng/mL, 95% confidence interval 
[95%CI]: 0.68 to 4.12). In the placebo group, the SD of the logarithm of the 
vitamin K1 level, used as the regression coefficient in the linear regression 
model, was 0.52. The SD of ln(vitamin K 2,3-epoxide) was 1.05. 
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Table 3 shows the associations between vitamin K status and time in 
therapeutic range, for the placebo group and the vitamin K group 
separately. In the placebo group, time in therapeutic range increased 3.4% 
for each SD increase in serum vitamin K1 (95%CI:  0.3 to 6.6%). An effect 
in the same direction was observed for serum vitamin K 2,3-epoxide: one 
SD increase resulted in a rise of the time in range of 2.7% (95%CI: -0.5 to 
5.8%). Adjustment for age, sex and use of co-medication did not change the 
results. When we combined vitamin K1 and vitamin 2,3-epoxide in one 
model, the effect of vitamin K1 remained similar and the effect of vitamin 
2,3-epoxide disappeared. In the group receiving vitamin K supplementation 
there was no association between vitamin K status and the time in 
therapeutic range. 
The increase of the time in therapeutic range was attributable to a 
decrease in time above the therapeutic range rather than below the 
therapeutic range, i.e. high serum vitamin K1 levels prevented 
overanticoagulation (Tables 4a and 4b).  
 
Discussion 
We found that time in therapeutic range increases by approximately 3% for 
each standard deviation increase in vitamin K levels. This demonstrates that 
patients with a high vitamin K status have a more stable anticoagulation 
than individuals with a low vitamin K status. This relationship was found 
both for levels of vitamin K1 as vitamin K 2,3-epoxide. In the group 
receiving the vitamin K supplement we found no association between 
vitamin K status and time in therapeutic range, suggesting that instability 
caused by dietary vitamin K changes in patients was effectively reduced by 
the vitamin K supplement. 
Our findings are in agreement with earlier studies that focused on 
vitamin K intake. Patients with low vitamin K intake were shown to have a 
less stable anticoagulant control7 and a higher risk of subtherapeutic 
anticoagulation.8 Changes in dietary vitamin K intake influence the INR5;13;14 
and do so more when vitamin K intake is low.5;8 In addition, starting a low 
dose vitamin K supplement of 25 µg/day results in subtherapeutic INR 
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values in individuals with a low plasma vitamin K only.6 These studies imply 
that patients are more susceptible to changes in vitamin K intake when 
vitamin K status is low and suggest that supplementation of vitamin K may 
be beneficial, especially in vitamin K depleted patients. Two placebo-
controlled trials have been performed on the effect of vitamin K 
supplementation on quality of anticoagulant treatment. Sconce et al. studied 
70 atrial fibrillation patients with unstable anticoagulant control and 
randomized them to receive 150 µg of vitamin K or a placebo for six 
months.9 Vitamin K supplementation resulted in a decrease in the SD of the 
INR values and an increase of the percentage time in therapeutic range 
from 78% in the placebo group to 87% in the vitamin K group. The second 
trial, which was the basis for the study presented here, was conducted in 
200 unselected patients who had been using the vitamin K antagonist 
phenprocoumon for over a year.10 Vitamin K supplementation resulted in a 
small increase of time in therapeutic range from 85% in the placebo group 
to 89% in the vitamin K group. The larger effect in the trial by Sconce may 
have been caused because in this study unstable patients were selected, who 
may have had a lower vitamin K status and benefit more from 
supplementation. Indeed, the mean plasma vitamin K concentrations at 
baseline were 0.60 ng/mL in the vitamin K group and 0.69 ng/mL in the 
placebo group of the trial by Sconce, which is considerably lower than the 
level of 0.87 ng/mL in the placebo group of our study.  Unfortunately we 
did not measure serum vitamin K at baseline, so we could not perform a 
subgroup analysis on the effect of vitamin K supplementation conditioned 
on vitamin K status.  
A possible limitation of this study is that we determined the vitamin K 
status in a single day’s sample. Even though we used fasting blood samples, 
circulating vitamin K concentrations respond to daily changes in intake.15 
This may have resulted in misclassification of the exposure variables 
(vitamin K1 and vitamin K 2,3-epoxide levels). Because this misclassification 
is just as likely to have occurred in individuals with stable anticoagulation as 
in individuals with unstable anticoagulation, it is likely that this caused at 
most an attenuation of the observed effects, in which case the true 
association between vitamin K levels and stability would be stronger than 
observed here. 
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Changes in dietary vitamin K intake can be a significant factor in the 
stability of anticoagulant treatment. Our results contribute to the evidence 
that patients using vitamin K antagonists should not restrict their vitamin K 
intake, which is frequently advised. On the contrary, a vitamin K intake in 
the high normal levels should be advised to increase stability of 
anticoagulant treatment. In addition, these findings support the proposal of 
using a vitamin K supplement to improve quality of anticoagulant therapy. 
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Abstract 
Background 
Efforts to improve dosing quality in oral anticoagulant control include the 
use of computer algorithms. As current algorithms are simplistic and give 
dosage proposals in a small fraction of patients, we developed an algorithm 
based on principles of system and control engineering that gives proposals 
in nearly all patients. 
Objective 
To evaluate the new algorithm in clinical practice. 
Methods 
We conducted a double-blind randomized controlled trial among 712 
patients with an indication for long-term anticoagulant treatment at the 
Leiden Anticoagulation Clinic. We compared oral anticoagulant dosing 
supported by the new algorithm (ICAD) with the standard algorithm 
(TRODIS). 
Results 
The percentage of time spent in the therapeutic range was similar for the 
new and standard algorithm groups, 79.8% vs. 80.2% (difference 0.4%, 
95%CI: 1.7-2.6%). The new algorithm produced a dosage proposal in 
97.5% of visits, and the standard algorithm in 60.8% (difference 36.7%, 
95%CI: 35.4-38.0%). Of proposals of the new algorithm, 79.3% were 
accepted by the physician vs. 90.9% for the standard algorithm (difference 
11.6%, 95%CI: 10.2-13.0%). This implies that the new algorithm gave an 
acceptable proposal in 77.4% of all patient visits vs. 55.3% for the standard 
algorithm (difference 22.1%, 95%CI 20.4-23.8%). 
Conclusion 
Substantially more dosage proposals were generated and accepted with the 
new than with the standard algorithm, and the new algorithm will therefore 
improve the efficiency of anticoagulant monitoring without loss of quality. 
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Introduction 
Management of oral anticoagulant treatment is difficult, because of the large 
variability in the dosage needed to achieve the optimal anticoagulant effect. 
Not only does sensitivity to vitamin K antagonists differ between patients, 
within patients, it may vary over time.1 
The use of computer algorithms to assist physicians with their dosing 
decisions has been shown to lead to equal or improved quality of control of 
oral anticoagulant treatment as compared to unassisted dosing.2-6 Several 
algorithms have been developed previously. Poller et al.4 compared three 
different computerized systems to assist warfarin control with traditional 
dosing by experienced doctors. They found roughly similar results for 
unassisted dosing by physicians and dosing by the three algorithms. In a 
larger multicenter study, Poller et al.5 evaluated the safety and efficacy of the 
DAWN AC anticoagulant therapy management system. They found that 
patients in the computer-dose group spent more time in the target range 
than patients in the traditional-dose group. An algorithm that is similar to 
these algorithms is used widely in the Netherlands (TRODIS).7 This 
algorithm generates a dosage proposal in approximately 55% of visits, 
leaving 45% for unassisted dosing by experienced physicians. In 
approximately 20% of cases where TRODIS generates a dosage proposal, it 
is overruled by a physician.8 All these algorithms are based on an empirical 
decision-tree that determines whether the same dosage can be maintained, 
dosage adjustments have to be made, or manual intervention by a physician 
is required. The equations used by the algorithm are based on a simple 
pharmacodynamic model, which implies a linear function between the 
International Normalized Ratio (INR) and the dosage. Major disadvantages 
of these algorithms are that they do not generate a dosage proposal in all 
cases, and they do not take into account the sensitivity of the patient to 
coumarin derivatives (which may change over time), the half-life of the 
drug, and the non-linearity of the dose-INR relationship. 
To improve computer-assisted dosing, we developed a new dosing 
algorithm. The improved control of anticoagulant dosage (ICAD) algorithm 
is based on a model that comprises the pharmacokinetics and 
pharmacodynamics of the oral anticoagulant drug, the pharmacokinetics of 
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the prothrombin complex, and the relationship between the activity of the 
prothrombin complex and the measured INR. It consists of two sub-
models: the first sub-model describes the collective influence of all 
processes on the effect of the vitamin K antagonist, and the second sub-
model describes the relationship between the dosage and the corresponding 
INR. The second sub-model includes a variable parameter to reflect the 
sensitivity of the patient, which may change over time. In an expert 
evaluation, 194 visits were randomly selected from the anticoagulation clinic 
database to assess whether the dosage proposal and appointment periods 
calculated by the algorithm were acceptable. In this evaluation, the ICAD 
algorithm was able to give a good or acceptable proposal in 94.3% of cases. 
The ICAD algorithm is described in detail elsewhere.9 In this study, we 
tested the ICAD algorithm in clinical practice in a double-blind randomized 
controlled trial, with the frequently used algorithm ‘TRODIS’  as the 
reference intervention. 
 
Methods 
Study design 
The study was conducted at the Leiden Anticoagulation Clinic in The 
Netherlands. Patients visit the clinic to have their INR measured, and they 
receive their daily dosage prescription the next day by mail.10 The TRODIS 
program uses the previous two INRs, the previous dosage schedule, the 
INR target, and range-limiting values of the INR. A dose-response model is 
used to predict an INR. By comparing this prediction with the measured 
INR, the program computes a new dosage and the time to the next visit. It 
does not generate a proposal in the case of an alert (e.g. when a new drug is 
prescribed) or a large difference between the actual and the target INR, and 
in that case the physician has to determine the dosage without any help 
from the algorithm. 
The ICAD algorithm also uses the actual measured INR, the target 
INR and the previous dosage schedule, but differs from TRODIS and all 
other algorithms by calculating the sensitivity of the patient over the full 
course of each treatment. This sensitivity is incorporated in the equation to 
estimate the dosage needed to achieve an optimal anticoagulant effect, thus 
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allowing the dose-INR relationship to change over time. Like all other 
algorithms, the ICAD algorithm gives a recommendation for the dosage as 
well as an appointment period. A computer program was developed for this 
study to present the dosage proposals of both algorithms in an identical way 
to keep physicians blinded. This program extracted for every patient the 
dosage proposal generated by TRODIS along with the INR, previous 
dosage schedule, and all previous INRs from the TRODIS mainframe 
database. The relevant data were fed through the ICAD algorithm, and an 
ICAD proposal was generated; thus, for all patients, a TRODIS as well as 
an ICAD proposal was available. Depending on which group the patient 
was randomized to, the TRODIS or the ICAD proposal was shown to the 
physician, on a screen that was identical for both types of proposals. Along 
with the dosage proposal, a recommendation about the appointment period 
was given. Both ICAD and TRODIS give an indication of how confident 
the algorithm is about the proposal; for TRODIS, there are two levels of 
confidence (‘high’ and ‘tentative’), whereas ICAD expresses confidence in a 
range of 0-100. These levels of confidence were not shown to the physician 
to maintain blinding, but are used in the analyses presented here. The 
physician could either accept or overrule the generated proposal. The final 
dosage was fed back to the mainframe database of the anticoagulation clinic 
and subsequently, as is the routine policy, communicated by mail to the 
patient. 
 
Patients 
Enrollment occurred between 14 August and 16 October 2003 at the 
Leiden Anticoagulation Clinic. Patients were eligible when they were already 
receiving anticoagulation with an indication for long-term anticoagulant 
therapy, and were aged between 18 and 80 years. Patients were excluded 
when they were on patient self-management, stayed long periods abroad, or 
were in a terminal stage of disease. Randomization was stratified by the 
indication for oral anticoagulant treatment, age and sex using the 
minimization method.11 The study was double blind; that is, neither patients 
nor physicians were aware of which group the patient belonged to. Follow-
up was until 1 September 2004, i.e. maximally about 1 year.  
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We obtained approval from the Medical Ethics Review Committee of 
the Leiden University Medical Centre before the start of the study, and each 
patient gave written informed consent. Trial Registration: ISRCTN register, 
http://www.controlled-trials.com. Identifier ISRCTN27801917. 
 
Analysis 
The analysis was performed at two levels, i.e. at the level of the patient and 
at the level of the proposal. In the first analysis, the primary outcome 
measure for this comparison was quality of anticoagulant treatment, defined 
as the mean percentage of time spent in the therapeutic range (TTR), 
calculated by the linear interpolation method.12 Therapeutic ranges were as 
applied in our routine anticoagulant practice: INR 2.0-3.5 for low intensity, 
and INR 2.5-4.0 for indications requiring a higher intensity. If a patient had 
two or fewer INR measurements in total, no TTR was calculated. When the 
time between two INR checks exceeded 9 weeks, no TTR was calculated 
for this period, and this period was excluded. All periods of hospitalization 
were excluded. 
Secondary outcome measures were the median time between visits, the 
percentage of time above or below the therapeutic range, the number of 
dosage proposals generated by the algorithm, and clinical events. Bleeding 
complications were classified as major if they were fatal or necessitated 
hospitalization. Minor bleeding complications were all other bleeding 
events, in which ecchymoses were only counted when more than 10 cm in 
diameter, and epistaxis only when the duration exceeded 30 min.  
In the analysis at the level of the proposal, we compared the proposals 
as they were generated by each algorithm (only one was shown to the 
physician). The primary outcome measure was the quality of the dosage 
proposals, expressed as the percentage accepted by the physician. If no 
proposal was generated, we considered this as not accepted. Secondary 
outcomes at the level of proposal comparisons were the percentage of INRs 
within the therapeutic range at the next visit, the percentage of accepted 
appointment periods proposed by the algorithms, and whether the dose 
proposal of the algorithm that was not shown to the physician differed 
from the given dose.  
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We knew beforehand that TRODIS is not always capable of generating 
a dosage proposal. If the algorithm was incapable of generating a proposal, 
the dosage had to be determined by the physician unassisted by the 
algorithm. ICAD generated a dosage proposal in nearly all visits, which 
made it possible to directly compare ICAD with the physician. To avoid 
bias, we selected all INR checks from both randomization groups where 
TRODIS was not able to generate a proposal. This was possible because, 
for all visits, an ICAD as well as a TRODIS proposal was available. For 
patients randomized to TRODIS, the physician determined the dosage 
without assistance from the algorithm. In the patients randomized to 
ICAD, an ICAD proposal was available. We studied the performance of the 
physician vs. ICAD in these two groups by calculating the percentage of 
INRs within range at the next visit. 
 
Statistical analysis 
We determined the necessary sample size on our primary outcome measure, 
the therapeutic range. We felt a difference of 5% in percentage of time 
spent in the TTR to be of clinical relevance. On the basis of information 
from several anticoagulation clinics, we found an SD of approximately 23% 
in this outcome measure. With an alpha of 5% and a power of 90%, we 
needed two times 168 patients to detect our clinically relevant difference. 
To allow us to do subgroup analyses, we included 712 patients. 
All outcomes are shown as means or percentages with the 
corresponding 95% confidence interval (95%CI) of the difference based on 
T or binomial distributions or medians with the corresponding interquartile 
range (IQR). All calculations were performed on an intention-to-treat basis 
using the statistical package SPSS version 14.0 (SPSS Inc., Chicago, IL, 
USA).  
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Results 
Seven hundred and twelve patients were randomized; 359 were assigned to 
ICAD, and 353 to TRODIS. The total follow-up time in the ICAD group 
was 283.1 person-years, during which 6 007 INR checks were performed. In 
the TRODIS group, the follow-up time was 278.7 person-years, with 5 920 
INR checks. Enrolment, randomization, follow-up and analysis of all 
patients are summarized in Figure 1. Baseline characteristics are shown in 
Table 1.  
 
Figure 1: Enrollment, randomization and data analysis 
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Table 1: Patient characteristics 
  TRODIS 
(n = 353) 
ICAD 
(n = 359) 
Age (years)   
 Mean (IQR) 65.7 (59.6-74.8) 64.6 (57.6-74.8) 
Sex   
 Men (%) 66.6  66.6  
Indication   
 Atrial Fibrillation (%) 44.5  42.3  
 Venous thrombosis (%) 11.6  13.3  
 Heart valve prosthesis (%) 9.9  10.6  
 Other cardiac indication (%) 20.1  16.7  
 Peripheral vascular disorder (%) 8.8  10.3  
 Cerebrovascular (%) 5.1  7.0  
Coumarin   
 Acenocoumarol (%) 13.6  12.5  
 Phenprocoumon (%) 85.6  86.1  
 Switched (%) 0.8  1.4  
Intensity (target)   
 Low (2.5-3.5) (%) 62.9  61.6  
 High (3.0-4.0) (%) 36.3  38.2  
 Switched (%) 0.8  0.3  
 
 
 
 
 
The mean TTR was 79.8%in the ICAD group and 80.2% in the 
TRODIS group (difference 0.4%, 95%CI of difference: -1.7 to 2.6%). The 
mean percentage of time spent at subtherapeutic or supratherapeutic INRs 
did not differ: 4.2% of time subtherapeutic in the ICAD group vs. 4.4% in 
the TRODIS group (difference 0.2%, 95%CI: ‐1.1 to 1.5%), and 16.0% of 
time supratherapeutic in the ICAD group vs. 15.4% in the TRODIS group 
(difference 0.6%, 95%CI: ‐1.1 to 2.3%). The median time between two 
visits in the ICAD group was 14 days (IQR 14-26 days) vs. 14 days (IQR 
14-22 days) in the TRODIS group (Figure 2). 
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Figure 2: Time between two visits 
 
There were 98 bleeding events (17 major and 81 minor) and three 
thromboembolic complications in 85 patients. Overall incidences of clinical 
thromboembolic and bleeding events (allowing for more than one event per 
patient) were 19.4/100 person-years in the ICAD group vs. 16.5/100 
person-years in the TRODIS group, yielding a relative risk of 1.2 (95%CI: 
0.8-1.8). Twelve of the major bleeding events occurred in the ICAD group 
(incidence rate 4.2/100 person-years), and five in the TRODIS group 
(incidence rate 1.8/100 person-years). This yielded a relative risk of 2.3 
(95%CI: 0.8-6.5) of excess bleeding in the ICAD group vs. TRODIS group. 
In the ICAD group, the major bleeding events were as follows: five 
gastrointestinal, two hematuria, one severe nose bleed, and one severe skin 
bleed. Three patients had a fatal intracranial bleed. In the TRODIS group, 
there were two severe nose bleeds, one respiratory tract bleed, and one 
retroperitoneal bleed. One patient had a fatal intracranial bleed. To further 
investigate the major bleeding events, we analyzed, in addition to the mean 
TTR, time spent with an INR < 2.0, 2.0-3.0, 3.0-4.0, 4.0-5.0, and above 5.0. 
Also in this analysis, there was no difference between the ICAD group and 
the TRODIS group. For 11 patients, an INRmeasurement was available at 
the time of bleeding. All INRs were between 1.3 and 3.7, except for one 
patient who had an INR of 4.3 (TRODIS group). Of the remaining 
patients, two had an INR measurement 2 days before the event: INR of 2.4 
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(TRODIS) and 1.3 (ICAD). In none of the patients was the dosage 
increased at the last INR measurement. In total, 21 patients died during 
follow-up, four because of a bleeding complication (three ICAD, one 
TRODIS). All deaths and complications are listed in Table 2. 
 
Table 2: Adverse events and deaths during follow up. 
  TRODIS 
(n=349) 
ICAD 
(n=350) 
Bleeding events   
 Minor 40 41 
 Major 4 9 
 Fatal 1 3 
 Total 45 53 
Thromboembolic events 1 2 
Deaths   
 Bleeds 1 3 
 Malignancy 1 2 
 Cardiac 2 0 
 Respiratory 0 3 
 Other 1 1 
 Unknown 4 3 
 Total 9 12 
 
ICAD was able to generate dosage proposals in 97.5% of visits, 
whereas TRODIS generated a proposal in 60.8% (difference 36.7%, 
95%CI: 35.4-38.0%). In the ICAD group, 79.3% of these dosage proposals 
were accepted vs. 90.9% in the TRODIS group (difference 11.6%, 95%CI: 
10.2-13.0%). In total, therefore, 77.4% of patient visits in the ICAD group 
led to an accepted proposal, as opposed to 55.3% in the TRODIS group 
(difference 22.1%, 95%CI: 20.4-23.8%). In the ICAD group, software 
problems were the main reason for not generating a proposal; these 
occurred only rarely. The most important reason for rejecting a proposal 
was that the dosage change proposed by the algorithm was estimated to be 
too strong (60.5%). In the TRODIS group, the main reason why a proposal 
was not generated was an INR change that was too large in relation to the 
previous INR or the one before that (64.2%). In the case of a rejected 
proposal, this was mostly because the dosage change proposed by the 
algorithm was too strong (66.2%) (Table 3). 
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Table 3: Reasons for not accepting a dosage proposal. 
 ICAD 
(n = 1211) 
TRODIS 
(n = 328) 
Reasons N (%) N (%) 
Dose change proposed by the algorithm was too strong 733 (60.5) 217 (66.2) 
Dose change proposed was not strong enough 339 (28.0) 60 (18.3) 
Proposal was in the wrong direction 139 (11.5) 51 (15.5) 
 
 
When the proposals were stratified according to the confidence level 
that the algorithm had given to them, in both groups the proportion of 
proposals that was accepted rose with the confidence level (Table 4). Along 
with the dosage proposal, the algorithms also provided proposals for the 
appointment period. The proposed appointment periods were accepted in 
76.5% in the ICAD proposals and in 91.4% in the TRODIS proposals 
(difference 14.9%, 95%CI of difference: 13.5-16.3%). When we considered 
only proposals for which the physician accepted the dosage, 82.1% of the 
ICAD appointment periods were accepted, and 93.4% of those in the 
TRODIS group (difference 11.3%, 95%CI of difference: 9.9-12.7%). 
 
 
Table 4: Percentage of accepted dose proposals stratified according to the confidence 
levels. 
 n (%) % Accepted 
TRODIS proposal type   
 No proposal 2319 (39.2) 0 
 Tentative 1465 (24.7) 87.6 
 Confident 2136 (36.1) 93.1 
 Total 5920 55.3 
ICAD confidence score   
 0-20 228 (3.8) 7.9 
 20-40 367 (6.3) 37.3 
 40-60 939 (15.6) 64.9 
 60-80 2001 (33.3) 80.1 
 80-100 2472 (41.2) 92.4 
 Total 6007 77.4 
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In the ICAD group 70.1%of INRs were in range at the next visit, as 
compared to 72.5% of INRs in the TRODIS group (difference 2.4%, 
95%CI of difference: 0.7-4.1%). When we only considered the accepted 
proposals, 72.3% of the INRs were in range in the ICAD group, vs. 75.7% 
in the TRODIS group (difference 3.4%, 95%CI of difference: 1.4-5.4%). Of 
the TRODIS proposals that were overruled by the physician, 28.0% had an 
ICAD proposal that was equal to the dosage that was given by the 
physician. In the ICAD group, 19.1% of the unaccepted proposals had a 
TRODIS proposal that was similar to the actual given dosage. 
In the comparison between ICAD and the physician, i.e. all patient 
visits where TRODIS was not capable of giving a proposal, ICAD was able 
to generate a dosage proposal in 96.9% of cases. Of these, 66.7% were 
accepted by the physician. In the ICAD group, 63.4%of the INRs were 
within the therapeutic range at the next INR measurement vs. 67.4% in the 
TRODIS group, which were dosed by the physician (difference 4.0%, 
95%CI of difference: 1.2-6.8%). 
 
Discussion 
In this study, we compared two computer algorithms for the control of 
anticoagulant dosing. There was no difference in quality of anticoagulant 
control between the TRODIS and the ICAD algorithms, expressed as mean 
TTR. Also, the time between two visits was similar in both groups, although 
the IQR was broader for the new algorithm. There was a difference in 
efficiency between the two algorithms. For all visits, TRODIS generated an 
acceptable proposal in 55.3%, as opposed to 77.4% for ICAD. Finally, in 
almost all cases where the standard algorithm could not give a proposal, the 
new algorithm could, and performed equally well as an unassisted physician. 
The similar quality of ICAD and TRODIS proposals can be explained 
in several ways. Firstly, it is possible that an algorithm that uses more 
information on a patient is not capable of generating dosage proposals 
better than an algorithm that uses less information. Secondly, it is possible 
that there can be no more gain in quality of treatment by improving dosing 
of anticoagulants. Thirdly, physicians, being used to the old algorithm, may 
have altered unusual but good proposals of the new algorithm. We feel that 
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it is unlikely that an algorithm will ever be capable of incorporating all 
aspects of patient behavior, such as sudden changes in diet, and that 
possibly the best that is attainable is an algorithm that does as well as well-
trained, dedicated physicians. When one algorithm uses a simple model and 
only gives proposals for ‘easy’ cases, leaving the more difficult cases to the 
physicians, while another algorithm gives proposals for virtually all cases 
and performs as well as the physicians, we would expect the result to be as 
we observed: an increase in efficiency without a concomitant increase in 
quality of treatment. 
Although there was no difference in mean TTR between the groups, we 
did observe a difference in clinical events. As the study groups were similar 
in all prognostic variables, and the TTR was similar for both groups, we feel 
that this was due to chance. Also, in the additional analysis, we again found 
no difference between the two groups, and most bleeding events were at 
INR in range, which strengthens our idea that the difference was due to 
chance. 
This study was double blind, so patients in both groups were treated in 
the same way except for the algorithm that was used. Bias resulting from a 
different attitude towards the two algorithms was therefore prevented. In 
some cases, blinding of the physicians could not be achieved. It was known 
beforehand that TRODIS is often not able to generate a proposal. 
Whenever there was no proposal available, the physician knew that in all 
likelihood this concerned a patient randomized to the TRODIS group. This 
was only known for the INR check at that time, for the physician did not 
see previous proposals. Because in these cases there was obviously no 
possibility of rejecting or accepting the proposal, it is difficult to imagine 
that this could have biased the results. 
Some patients were lost to follow-up after randomization because of 
participation in a self-management program, end of the prescribed 
treatment period, or other reasons. In both groups, the same number of 
patients was lost to follow-up, and their numbers were small, so selection 
because of loss of patients is unlikely. 
We have tested the new ICAD algorithm for computer assisted dosing 
of oral anticoagulants in a randomized blinded comparison with the 
algorithm that is currently in use. The ICAD algorithm led to a similar 
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quality of anticoagulant control, but performed more efficiently: overall, the 
proportion of proposals accepted was 77.4%, vs. 55.3% for the old 
algorithm. Of course, we compared the ICAD algorithm only with 
TRODIS, and it is possible that other results would have been obtained if a 
comparison had been made with other systems used for computer-assisted 
dosing. In our opinion, however, the newly developed ICAD algorithm 
represents an important gain in the efficiency of the management of oral 
anticoagulant therapy. 
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Summary & discussion 
The main objective of this thesis was to test the hypothesis that the INR is 
particularly sensitive to changes in vitamin K intake when vitamin K status 
is low, and that patients with a low vitamin K intake would therefore have 
an increased risk of unstable anticoagulation. We approached this problem 
in three ways. We looked at the effects of dietary vitamin K intake, of 
vitamin K status as assessed by serum assays and of administration of a 
vitamin K supplement.  
In chapter 3 we studied the effect of dietary vitamin K intake on the 
occurrence of subtherapeutic INRs. We determined the effect of usual 
vitamin K intake, consumed over a longer period of time, in a prospective 
cohort study. Within this cohort a nested case control study was performed 
to test whether an incidental high vitamin K intake results in a low INR and 
whether it does so more often in people with a low usual vitamin K intake. 
We found the risk of subtherapeutic INRs to be highest in individuals with 
a low usual vitamin K intake and lowest in those with a high usual intake. 
And we found that an incidental increase in vitamin K intake is a risk factor 
for a low INR exclusively in individuals with a low usual vitamin K intake.  
In chapter 5 we investigated whether supplementation with a low daily 
dose of vitamin K improves anticoagulant control in a double-blind 
randomized placebo-controlled trial. Patients were randomized to receive 
either adjusted-dose phenprocoumon and 100 µg vitamin K once daily or 
adjusted-dose phenprocoumon and a placebo. The choice for the 100 µg 
vitamin K supplement was made based on the pilot study described in 
chapter 4. In this chapter we determined the effect of escalating daily doses 
of vitamin K on the required dose of phenprocoumon. We found that a 
vitamin K supplement of 100 µg per day can safely be given on the 
condition that the INR is monitored frequently after starting and stopping 
the supplement to allow timely dose adjustments. In the trial, quality of 
anticoagulant control, expressed as time in therapeutic range (TTR) 
increased from 85.5% in the placebo group to 89.5% in the group receiving 
the vitamin K supplement. This improvement was attributable to a decrease 
in time above the therapeutic range rather than below the therapeutic range. 
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In the same trial we looked at the association between vitamin K status 
in serum and stability of anticoagulant treatment. The results are shown in 
chapter 6. In the placebo group each standard deviation (SD) increase in 
vitamin K1 serum levels was associated with a 3.4% higher TTR. Vitamin K 
2,3-epoxide increased the TTR with 2.7% per SD. In the group receiving 
the vitamin K supplement we found no effect of vitamin K status on the 
TTR, indicating that vitamin K status had no deleterious effect when 
patients were adequately supplemented. 
The results of these three studies, using different methods, all confirm 
our hypothesis that patients with a poor vitamin K intake have reduced 
stability of anticoagulation. This has several implications. First of all, 
patients using VKAs should be advised to keep an adequate vitamin K 
intake. Secondly, supplementation of vitamin K may improve quality of 
anticoagulant treatment, especially in individuals with low vitamin K status. 
And finally, in ill patients, who are likely to have a low vitamin K status, 
small doses of vitamin K might be sufficient to correct overanticoagulation. 
The recommendation for patients using VKAs to keep vitamin K 
intake adequate is supported by other studies1-4 and is gaining acceptance5;6. 
This is in disagreement with earlier recommendations to limit or avoid 
foods high in vitamin K7. It seems rational to advise people to keep their 
vitamin K intake constant.4;8-10 To combine these recommendations, 
keeping vitamin K intake constant and adequate, the most practical advice 
would be to adhere to a healthy diet that is suggested for the population in 
general: To consume 200 grams of vegetables and two pieces of fruit each 
day.  
The recommendation to give a vitamin K supplement to improve 
stability of anticoagulant treatment is supported by other work as well11;12.  
Sconce et al. performed a randomized controlled trial similar to ours, but 
they included solely patients with unstable anticoagulant control. They 
found an increase in TTR from 78% in the placebo group to 87% in the 
vitamin K group. The larger effect in this trial than in ours may be caused 
by a lower vitamin K status in these unstable patients than in the patients in 
our trial, who were an unselected group of users of VKAs. A 4% increase in 
TTR seems too low a benefit to recommend vitamin K supplementation in 
all VKA users, but may be worthwhile in unstable patients or patients with 
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a low vitamin K intake. Indeed, it has been accepted as a recommendation 
in the Clinical Practice Guidelines of the American College of Chest 
Physicians: “For patients receiving long-term warfarin therapy with a 
variable INR response not attributable to any of the usual known causes for 
instability, we suggest a trial of daily low-dose oral vitamin K (100 to 200 
µg), with close monitoring of the INR and warfarin dose adjustment to 
counter an initial lowering of the INR in response to vitamin K”.13 This is 
graded as a 2B recommendation, meaning that it is a weak recommendation 
based on moderate-quality evidence14. Future research should aim at 
identifying patients who benefit the most from supplementation (e.g. 
patients with unstable anticoagulant control, patients with low vitamin K 
intake or vitamin K status). Furthermore, the effect of a supplement on 
clinical endpoints should be evaluated.  
Vitamin K is widely used to correct overanticoagulation.13;15-17 Different 
doses are suggested for different levels of overanticoagulation13. But the 
effect of a single dose of vitamin K for a particular INR value differs 
between patients18. This can probably be partly explained by a different 
vitamin K status in patients. To our knowledge no studies have been done 
on this matter. It would be worthwhile to investigate whether establishing 
the vitamin K dose based on measured or presumed vitamin K status gives 
better outcomes than using an algorithm based on the INR only.  
 
In chapter 7 two computer algorithms for VKA dosing are compared in a 
double-blind controlled trial. The standard algorithm is based on 
pharmacodynamics of the VKA only, the new one includes 
pharmacokinetics and pharmacodynamics of the VKA, pharmacokinetics of 
the prothrombin complex, and the relationship between the activity of the 
prothrombin complex and the measured INR. We found no differences 
between the two algorithms in quality of anticoagulation or time between 
visits. The new algorithm did, however, result in more efficient dosing, 
since it gave a proposal in nearly all cases.  
 
Chapter 2 describes the results of a study on occurrence of subtherapeutic 
INRs. In this cohort study in 13 443 patients of the Leiden anticoagulation 
clinic, 7 419 met the criteria for stability defined as four consecutive INRs 
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within the therapeutic range. Within four weeks of this stable period, 12% 
of patients had experienced a subtherapeutic INR and after 40 weeks this 
increased to 50%. Use of acenocoumarol doubled the risk of a 
subtherapeutic INR compared to phenprocoumon. The risk was also 
increased in patients with an indication for high intensity treatment and in 
patients who used VKAs as prophylaxis for venous thrombosis. In 30% of 
cases the subtherapeutic INR was preceded by an event that justified 
intentional lowering of the INR: An invasive procedure, haemorrhage or 
overanticoagulation. 
 
The research described in this thesis provides insight in what causes 
unstable anticoagulant control, and subtherapeutic anticoagulant control in 
particular. The association between unstable control and adverse clinical 
outcomes has been convincingly established. Any decrease in time below 
and above the therapeutic range will result in fewer thrombotic and 
bleeding events, respectively. However, quality of anticoagulant control 
expressed as time in, above or below the therapeutic range remains a 
surrogate endpoint. Results such as described in this thesis are important to 
direct large randomized trials that are required to assess the effects on 
clinical endpoints. 
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Samenvatting 
Vitamine K antagonisten zijn antistollingsmiddelen in tabletvorm. Ze 
worden voorgeschreven voor de behandeling en preventie van trombose. 
Zowel arteriële trombose (trombose van de slagaderen, bv hartinfarct, 
herseninfarct) als veneuze trombose (trombose van de aderen, bv 
trombosebeen en longembolie) worden effectief voorkómen door 
vitamine K antagonisten. Aangezien dit frequent voorkomende 
aandoeningen zijn, worden antistollingsmiddelen veel voorgeschreven: Elk 
jaar gebruiken zo’n 300 000 Nederlanders vitamine K antagonisten. 
De keerzijde van de behandeling met deze medicijnen is het risico op 
bijwerkingen. De belangrijkste bijwerking is het optreden van bloedingen. 
Ernstige bloedingen treden op bij zo’n 2% van de behandelde patiënten per 
jaar, fatale bloedingen bij ongeveer 1 op de 200 patiënten per jaar. Het risico 
op een bloeding neemt toe naarmate de intensiteit van de antistolling hoger 
is. Aan de andere kant neemt het risico op trombose weer toe bij een lagere 
intensiteit. Deze intensiteit kan worden gemeten in het bloed en wordt 
uitgedrukt als de INR (International Normalized Ratio). De INR heeft als 
uitgangspunt de normale waarde voor mensen die geen 
antistollingsmiddelen gebruiken, gesteld op 1.0. Afhankelijk van de indicatie 
voor de behandeling wordt bij patiënten gestreefd naar een INR tussen de 
2.0 en 4.0. Bij een INR onder de 2.0 neemt de kans op trombose toe, bij 
een INR boven de 4.0 neemt de kans op een bloeding toe. 
Het is dus belangrijk om de INR binnen het streefgebied te houden. 
Helaas zijn er vele factoren die van invloed zijn op het effect van 
antistollingsmiddelen en dus op de hoogte van de INR. Eén van die 
factoren is de vitamine K inname in het dieet. Vitamine K komt voor in ons 
voedsel, met name in groene groenten, zoals boerenkool en spinazie. 
Vitamine K is nodig voor een normale stolling. Vitamine K antagonisten 
gaan de werking van vitamine K tegen en zorgen er zo voor dat het bloed 
minder stolbaar wordt gemaakt. Omdat wij elke dag iets anders eten, wisselt 
onze vitamine K inname en daarmee de intensiteit van de antistolling.  
Tot voor kort was het advies aan patiënten die antistollingsmiddelen 
gebruiken om de vitamine K inname constant te houden en 
voedingsmiddelen met een hoog vitamine K gehalte te mijden. Maar het 
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mijden van vitamine K- rijke groente betekent een lagere totale vitamine K 
inname en er zijn de laatste tijd steeds meer aanwijzingen gekomen dat 
patiënten met een lage vitamine K inname minder stabiel ingesteld kunnen 
worden op antistollingsmiddelen. Dit zou verklaard kunnen worden 
doordat schommelingen in de vitamine K inname een relatief grotere 
invloed hebben bij een lagere vitamine K status. Het belangrijkste doel van 
dit proefschrift was om deze hypothese te toetsen en om het bewijs te 
versterken voor de veronderstelling dat een hoge vitamine K inname leidt 
tot een stabielere antistolling.  
Een tweede aandachtspunt was het optreden van lage INRen. Het zit in 
de aard van artsen en wetenschappers om meer aandacht te geven aan de 
schade die we aanbrengen door overbehandeling dan door 
onderbehandeling. Dit uit zich in de wetenschappelijke literatuur over 
antistollingsbehandeling door het grote aantal studies over het vóórkomen 
en voorkómen van bloedingen en hoge INRen, terwijl weinig bekend is 
over oorzaken van een te lage INR. Wij onderzochten hoe groot het risico 
is op een te lage INR en welke factoren hierop van invloed zijn. 
Tot slot richtten wij ons op het doseren van antistollingsmiddelen. Om 
de INR binnen de streefwaarden te houden wordt voor iedere individuele 
patiënt de dosering van het antistollingsmiddel bepaald. Elke 1-6 weken 
wordt de INR gemeten en zo nodig wordt de dosering aangepast. Bij het 
vaststellen van de optimale dosering wordt veelal gebruik gemaakt van 
computeralgoritmes. Eerder werd een nieuw computeralgoritme 
ontwikkeld, dat naast de relatie tussen de INR en de dosering van het 
antistollingsmiddel ook rekening houdt met de individuele gevoeligheid van 
een patiënt. Wij vergeleken dit nieuwe algoritme met een traditioneel 
algoritme. 
 
Het belangrijkste deel van dit proefschrift, het onderzoek naar de 
veronderstelling dat een hoge vitamine K inname leidt tot een stabielere 
antistolling, is opgenomen in de hoofdstukken 3, 4, 5 en 6. 
In hoofdstuk 3 onderzochten wij het effect van vitamine K inname in het 
dieet op het optreden van een te lage INR. We keken of een lage INR vaker 
optreedt bij een hoge of lage gemiddelde vitamine K inname (gemeten over 
vier weken) en wat het effect is van een incidentele hoge inname. Daarnaast 
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onderzochten we of juist bij mensen met een lage gebruikelijke vitamine K 
inname een incidentele hoge inname vaker een lage INR tot gevolg heeft. 
We vonden dat het risico van een lage INR het hoogst is bij mensen met 
een lage gemiddelde vitamine K inname en het laagst bij mensen met een 
hoge inname. Een hoge incidentele vitamine K inname verhoogt de kans op 
een lage INR uitsluitend in mensen met een lage gemiddelde inname.  
In hoofdstuk 5 bestudeerden wij of een dagelijkse toediening van een 
geringe hoeveelheid vitamine K de stabiliteit van antistollingsbehandeling 
kan verbeteren. In een experimentele studie werden patiënten willekeurig 
ingedeeld in een groep die naast de antistollingsbehandeling een supplement 
met 100 µg vitamine K innamen of in een placebogroep. De keuze voor de 
dosering vitamine K werd genomen naar aanleiding van een vooronderzoek 
dat wordt beschreven in hoofdstuk 4. In dit hoofdstuk bepaalden we wat het 
effect is van verschillende doseringen vitamine K op de benodigde dosis 
van het antistollingsmiddel om zodoende de dosering vast te stellen die 
hoog genoeg is om het gewenste effect te bereiken, maar die wel veilig kan 
worden gegeven. In de experimentele studie vonden wij dat de kwaliteit van 
antistollingsbehandeling, uitgedrukt als de tijd dat de INR binnen het 
streefgebied is (time in therapeutic range [TTR]), verbeterde van 85.5% in 
de placebo groep naar 89.5% in de groep die vitamine K kreeg. 
In dezelfde studie onderzochten we de relatie tussen stabiliteit van 
antistolling en de vitamine K status, uitgedrukt als het gehalte aan 
vitamine K en zijn metaboliet vitamine K epoxide in het bloed. De 
resultaten zijn weergegeven in hoofdstuk 6. In de placebogroep werd een 
relatie gevonden tussen stabiliteit van antistolling en het gehalte van zowel 
vitamine K als vitamine K epoxide: Mensen met een betere vitamine K 
status hadden een hogere TTR. In de groep die het vitamine K supplement 
kreeg toegediend, werd geen effect gevonden van de vitamine K status op 
de TTR, wat erop wijst dat vitamine K status geen invloed heeft op de 
stabiliteit van antistolling wanneer patiënten adequaat worden gesuppleerd. 
 
Hoofdstuk 2 beschrijft de resultaten van de studie naar de frequentie van 
voorkomen van een te lage INR en de risicofactoren. In totaal werden 
7 419 patiënten gevolgd, nadat ze stabiel waren ingesteld op 
antistollingsmiddelen. Na vier weken had 12% van de patiënten een lage 
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INR en na 40 weken was dit gestegen tot de helft. Het gebruik van het 
antistollingsmiddel acenocoumarol gaf een twee keer zo hoog risico op een 
lage INR vergeleken met een ander middel, fenprocoumon. Het risico was 
daarnaast afhankelijk van het streefgebied (hoger risico bij een hoger 
streefgebied) en de indicatie voor antistolling (hoger risico bij preventie van 
veneuze trombose en laagste risico bij patiënten met mechanische 
kunstkleppen). In 30% van de gevallen werd de lage INR voorafgegaan 
door omstandigheden die het opzettelijk verlagen van de INR 
rechtvaardigen; een operatie, ingreep, bloeding of een te hoge INR. 
 
In hoofdstuk 7 werden twee computeralgoritmes voor het doseren van 
antistollingsmiddelen met elkaar vergeleken. Het nieuw ontwikkelde 
algoritme, dat naast de relatie tussen de dosering en de INR ook rekening 
houdt met de gevoeligheid van de patiënt, werd in een experimentele studie 
vergeleken met een algoritme dat in Nederland veel wordt gebruikt. 
Patiënten werden willekeurig ingedeeld in groepen die werden gedoseerd 
met ondersteuning van het nieuwe dan wel het traditionele algoritme. Er 
werd geen verschil gevonden in kwaliteit van antistolling, uitgedrukt als de 
TTR. Ook de tijd tussen twee INR controles (de belasting voor de patiënt) 
was gelijk in beide groepen. Wel gaf het nieuwe algoritme vaker een 
dosisvoorstel dan het traditionele, waardoor het doseren mogelijk efficiënter 
kan worden. 
 
De resultaten van dit proefschrift verschaffen inzicht in factoren die van 
invloed zijn op de stabiliteit van antistolling, en met name op een te laag 
antistollingsniveau. Aangezien de relatie tussen stabiliteit van antistolling en 
klinische eindpunten (trombose en bloedingen) overtuigend is aangetoond, 
kan kennis over invloeden op de stabiliteit bijdragen aan het voorkómen 
van deze eindpunten.  
Onze belangrijkste conclusie is dat de hypothese kan worden bevestigd 
dat een hogere vitamine K inname leidt tot een stabielere antistolling. Wij 
hebben dit aangetoond in verschillende studies waarbij verschillende 
methoden werden gebruikt. Deze constatering heeft voornamelijk gevolgen 
voor het dieetadvies dat moet worden gegeven aan patiënten die vitamine K 
antagonisten gebruiken. Omdat vitamine K vooral zit in groenten is het 
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meest praktische advies zich te houden aan de aanbeveling van het 
Voedingscentrum voor de algemene bevolking: Eet elke dag twee ons 
groenten en twee stuks fruit.  
Het positieve effect van een vitamine K supplement lijkt vooralsnog te 
gering om op grote schaal te worden toegepast. Toekomstige studies 
moeten uitwijzen of suppletie klinische eindpunten kan voorkómen en of er 
subgroepen zijn die het meeste baat zouden kunnen hebben bij suppletie 
van vitamine K.  
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